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The Versatility of Ether-Bridged Cycloadducts Towards the Synthesis of Complex
Natural Products
Harold Deshaun Cooper, PhD
University of Connecticut, 2013
The presence of a heterocyclic moiety can be observed in many of today’s
bioactive natural products. One of the most commonly observed is furan, an aromatic
five-membered ring containing an oxygen atom. Furan is a simple compound, yet
versatile enough to be used as a synthetic synthon leading to complex structures such as
the antioxidant Phelligridin G and the antibacterial agent Platensimycin. In the former, it
is spiro-fused to the five-membered carbocycle of the 6-5-5 tricyclic domain while in the
latter it makes up the ether-bridged cycloadduct of the hydrophobic cage.
Conventionally, furan can undergo cycloadditions in the presence of reactive dienophiles
via the Diels-Alder reaction to form oxabicyclic synthons.
A strategy for the synthesis of the embedded spirocyclic core of phelligridin G
from a 2-phenylfuran system was developed. Finding a suitable dienophile compatible
with this biphenyl ring was a daunting task; however, we successfully obtained the
oxabicyclo[2.2.1]heptadiene intermediate upon surveying a plethora of available
dienophiles. Exposure of the strained ring system to the Grubbs’ 2nd generation
ruthenium-based catalyst facilitated a domino ring-opening metathesis/ring-closing
metathesis (ROM/RCM) to give a spiroannulated furan. Further evaluation showed the
highly reactive tetrachlorocyclopropene was a compatible dienophile leading to the
formation of spiro-fused pyran ring structures through a related metathesis approach.

Recently, we have developed a novel and expedient route towards the tetracyclic
caged domain of platensimycin using an oxabicyclo[3.2.1]octadiene building block.
Within our methodology a late-stage intermediate has been established from the [4+3]
cycloaddition of a substituted furan with tetrabromocyclopropene along with an
intramolecular γ–alkylation to form the seco-cage of this hydrophobic region. It has been
postulated that structural modifications could help improve its poor pharmacokinetic
profile while retaining potent bioactivity. Utilizing this furan-based route has led to the
synthesis of several novel analogues that will be evaluated for their antimicrobial activity
against methicillin-resistant Staphylococcus aureus (MRSA).

We have assembled a

unique derivative in which the cyclohexanone moiety has been replaced with the more
constricted cyclopentanone ring. A second series of analogues synthesized have the Cring completely removed from the caged domain and manipulation of the ketone
functionality was evaluated.
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CHAPTER 1
INTRODUCTION

Exploitation of Heterocyclic Chemistry: Studies on Furan Synthons
The ability to control functional group interchanges in an organic compound is
one of the most valuable tools for a synthetic chemist. This is a unique and practical skill
set that allows us to assemble a variety of natural products, which have led to some of the
world’s most recognized therapeutic agents. The intricate structural design of many
natural products allows the chemist to be creative and innovative when developing a
synthetic strategy. A highly functionalized intermediate can be used to build the most
complex organic molecules. A single chemical transformation, utilizing commercially
available starting materials such as furan, can lead to a considerable increase in molecular
complexity via a single step based upon new carbon-carbon bond formations. In 2001,
Wright published a review discussing how using the heterocycle furan as a synthetic
synthon toward complex polycyclic ring systems.1 There can be a variety of polycyclic
systems synthesized if an efficient method can be developed to synthesize polycyclic
furans. Being that furan is so versatile it can undergo numerous transformations such as
oxidations, reductions, or cycloadditions (Figure 1.1).

1

Figure 1.1 Synthetic equivalences of furan

Oxabicyclic Ethers
Furan Diels-Alder
The Diels-Alder reaction is one of the more recognizable approaches to give way
to oxabicyclic synthons. Formation of these bridged cycloadduct intermediates can take a
simple heterocyclic compound and transform it into something more structurally complex
in a single reaction. These oxabicyclic synthons also allow a great deal of stereo-and
chemoselective transformations to occur within the molecule to add more complexity.
The combination of furan and a reactive dienophile by this cycloaddition approach, one
of the most powerful and useful strategies to form functionalized aromatic rings, can lead
to the desired oxabicyclic systems (Figure 1.2). The versatile structures can be changed
to cyclohexenes by cleavage of the oxygen bridge or to a substituted tetrahydrofuran via
cleavage of the two-carbon bridge. Additionally, the oxygenated diene can undergo [4+3]
cycloadditions with oxyallyl cations to give various oxabicyclo[3.2.1]octane derivatives.
These intermediates can also serve as precursors to tetrahydrofurans, as well as pyrans
and cycloheptenes by cleavage of one of the three unique bridges.
2

Figure1.2 Utility of oxabicyclic synthons

Diels-Alder Cycloaddition [4+2]
Since its discovery in the first half of the 20th century the Diels-Alder
cycloaddition reaction has proved to be a compelling tool in the construction of today’s
most complicated organic molecules. Addition of highly reactive dienophiles such as
alkenes and alkynes tend to be resourceful for heterocyclic compounds. As previously
mentioned, the heterocycle furan can undergo various transformations via Diels-Alder
reaction; however, it has been found that certain substitutions at the C-2 or C-5 position
can hinder ether-bridged adduct formations. Presently there exist a number of published
articles on the use of furan in thermal cycloadditions; therefore, in this section the [4+2]
and [4+3] cycloadditions will be briefly examined.
In

2011,

Ogawa

and

co-workers

have

successfully

synthesized

3-

hydroxphthalates with the assistance of Lewis acid catalysts.2 Routes to these derivatives
proceed through a Diels-Alder cycloaddition accompanied by catalyst leading to a ringopening aromatization in a one pot synthesis. Isolation of the cycloadducts showed that
dimethyl acetylenedicarboxylate (DMAD) was a suitable dienophile for substituted furan
3

systems. Based on the fluctuation of desired product yields, it was found IrCl3.3H2O
catalyst influenced the reactivity rate more than FeCl3 or Cu(OTf)2 catalyst. Another
important factor was the type of substitution present in the C2 position. Presence of an
electron-donating group such as methyl exhibited good to excellent yields.

2-

Phenylfuran 1a produced the desired aromatic compound in good yields; however, the
oxabicyclic intermediate 3a was only 10% isolatable. Addition of electron-withdrawing
groups such as nitro, cyano, or trifluoromethyl groups to the 2-arylfurans dramatically
reduced the reactivity rates (Scheme 1.1).

Scheme 1.1 Diels-Alder reactions with 2-phenylfuran systems leading to 3-hydroxyphthalates

Higher-Order Cycloaddition [4+3]
Successful syntheses leading to an abundant number of complex natural products
have been reported by Wright and co-workers employing [4+3] cycloadditions. In the
Wright group, they have focused on forming bicyclo[3.2.1]octadienes between the
heterodiene furan and tetrahalocyclopropenes.3

The Wright group has utilized the

synthesis of oxabicyclic intermediates via cyclocondensation of di-substituted furan and
tetrabromocyclopropene. It has been known for some time that tetrahalocyclopropenes
can be directly converted to a series of analogous bicyclo[3.2.1]octadiene derivatives by
reaction with various dienes. It was first reported by Tobey and West in 1968 that
4

tetrachloro- and tetrabromocyclopropene were highly reactive dienophiles and underwent
Diels-Alder reactions under thermal conditions (Scheme 1.2).4 Once the cyclopropyl
norbornene 7 is derived, a spontaneous rearrangement occurs via migration of the
halogen atom to form oxabicyclo intermediate 8. A silver-promoted hydrolysis of the
tetrahalide leads to generation of the substituted enones 9 in a 2:1 ratio. This attack of the
cation by the water molecule is sterically influenced. The less hindered terminus is
preferentially attacked due to the shielding of the allyl system by the bridgehead alkyl
group.

Scheme 1.2 Development of the oxabicyclo[3.2.1]octadiene nucleus by halogen migration

Wright et al. show that these highly functionalized tetrahalobicyclo[3.2.1]octadienes can
be amended with good selectivities; however, studies conducted have shown that certain
reactive nucleophiles were unsuccessful in the addition to these bridged synthons.
Additions occur by 1,2 addition or 1,4 additions to form intermediates that can be applied
to the synthesis of natural products containing highly functionalized seven-membered
rings.
5

Techniques towards Spiroannulations
A common, yet challenging structural motif found in many natural products are
the spirocycles. These compounds consist of two rings joined together sharing only a
single carbon.

Over the years there has been a considerable amount of attention

dedicated to these types of organic compounds. Natural spirocycles are of great interest
to chemist because of their potential use as a novel therapeutic in addition to their
distinctive designs found in nature. In this section we will focus on a series of routes
developed to easily construct not only spiro-fused cycloalkanes, but the more exceptional
spiro-fused heterocycles.
Kumar and co-workers have utilized a Claisen rearrangement toward the
spiroannulation of cyclopentane rings that serve as precursors to the acorone and
isoacorone sesquiterpene ketones.5

Cyclohexane-1,4-dione underwent a sequence of

steps to give allyl alcohol 14 in good yield by way of a controlled Wittig-HornerEmmons reaction, protection of the ketone, and regiochemical reduction of 13
(Scheme1.3). Claisen rearrangement was crucial for the generation of the quaternary
center required in the formation of a spiro ring system. This process was thermally
activated in one pot with a catalytic amount of propionic acid and 2-methoxypropene led
to 16. After ozonolysis of the terminal alkene 14, spiroenone 17 was furnished via an
intramolecular aldol condensation facilitated by potassium hydroxide base.

Further

conversion transformed 17 into the desired spirodienone 18 through the prochiral
precursor 16 leading to the chiral acorones. This methodology served as a convenient
pathway to form the functionalized spiro[4.5]decane.

Furthermore, they performed

studies on the annulation of spiro-fused cyclopentanes leading to spiro-enones 23a-d.
6

Scheme 1.3 Spiroannulation of cyclopentane rings towards the synthesis of sesquiterpene ketones

Trost and co-workers have utilized a stereoselective approach to spirocycles
through ring contractions.6

Compound 26 was synthesized by the intercalation of 28

with β-keto sulfones 31 as a key intermediate to the spiro-fused molecules. Allowing the
β-keto sulfone to reflux for 3 hours in Lewis acid condition has led to the desired
spirocyclic isomers 26 only after quenching with ethanol. It was determined that the
transformation followed a pinacol type of rearrangement with the removal of the sulfone
group in acidic media (Scheme 1.4).

7

Scheme 1.4 Ring constriction to spiro-fused cyclopentenones
The rate of rearrangement depends on the size of the ring. Thermal conditions play a
vital role to get the appropriate product from intermediate 25. In order to achieve
complete isomerization of the β,γ isomer 25 to the α,β isomer 26 it was necessary to use
refluxing methylene chloride, which is considered the slow step in the reaction. At lower
temperatures they noticed after quenching the mixture only cyclized ketone 33 could be
isolated (Scheme 1.5). Controlling the alkylation of the keto-sulfone is correlated to
controlling the stereochemistry of 24. This cyclocontraction-spiroannulation route has
opened new dimensions to the usefulness of sulfones in total synthesis due to the
sensitivity of this functional group to Lewis acid ionization.

Scheme 1.5 Ring expansion leading to unsuccessful spiroannulations

8

In 2005, Undheim et al. created an efficient way to make bisarene type
compounds by way of forming rigid spirane bridged sandwich like polycyclic systems.7
There were assembled different ring sizes because they could control the rigidness of the
structure with the larger ring systems being more flexible than the smaller ones.
Annulations to form five-membered spirocycles had been previously reported via
alkylation of 2-oxocyclopentanecarboxylate followed by an acid catalyst with ptoluenesulfonic acid to form spiro[4.4]nonane-1,6 36 (Scheme 1.6). This route was not
as successful with the larger six-membered carbocycles. Further investigations led to a
new route to generate spiro[4.5]decane-1,6-dione 39 with the assistance of a rhodiumcatalyzed intramolecular acylation to the acetal 38. The solvent used along with the
presence of too much catalyst exhibited some decarbonylation; however, it was found
reducing the amount of [Rh(COD)Cl]2 by half while running the reaction neat increased
the yield of 39 to 90%. Ring closing metathesis (RCM), which is a more traditional
method, was found to be another procedure used to form these spirocycles. Addition of
Ru(II) catalyst to diene 40 after heating 3 hours led to the larger spiro[5.5]undecan-1,7dione 41 intermediate.

With these highly functionalized intermediates, further

transformations were employed resulting in the stereoselective α,α'-cis, cis-diaryl
spiranes 44a and 44b.

9
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Scheme 1.6 Preparation of spirane bridged systems towards bisarenes

As previously mentioned, a direct route to polycyclic ring closures is by using the
Ru(II)-catalyzed RCM which has been utilized by Kotha and co-workers for the
spiroannulation of barbituric acid derivatives.8

Besides the pharmaceutical value of

barbituric aid derivatives, they can also be useful building blocks to various complex
supramolecular structures. The strategies towards these potential novel analogs begin
with the available carbonyls 45 and 48 as starting materials. Each substrate was exposed
to two different approaches. The first would require the RCM of dialkenylated malonate
10

precursors 46. A second approach required presence of an active methylene group which
is then alkylated by an electrophilic terminal vinyl moiety to give 49 which undergoes
RCM to form spiro-fused diketone 50 (Scheme 1.7).

Scheme 1.7 Strategies towards the spiro-annulated compounds

Spiro-compound 56 is obtained upon a successful RCM reaction initiated by the 1st and
2nd generation Grubbs’ catalysts. Attempts to synthesize spiro-fused heterocycle 52 were
unsuccessful following the first strategy utilizing diethyl malonate 51. Malonate 55
formed spiro-annulated diester 56 upon exposure to Grubbs 1st generation catalyst at
room temperature in high yields; however, the hindered nature of the spirocyclic system
failed to undergo condensation with urea. Hence all reaction efforts were focused on the
alternate strategy which validates to be a better yielding route to a series of spiroannulated barbituric acid derivatives (Scheme 1.8).

11

Scheme 1.8 Ring closing metathesis as a key step to synthesizing barbituric derivatives and
analogs

A nontraditional methodology towards spirocyclic molecules have been
investigated by Swenton and coworkers using electrochemistry.9 These new carboncarbon bonds were prepared on phenol substrates containing an electron rich olefinic
substituent to identify the competing reactions within the molecule. Studies on substrate
65 showed that the yield of anodic cyclization was affected by the location of the double
bond (Scheme1.9). This electron rich intermediate was assembled by combining the
ketone 62 and 63 followed by acid-catalyzed dehydration of 64. Anodic oxidation of the
12

vinyl aromatic system gave spiro-fused 66 in good yield. The addition of the methyl
group forces the vinyl linker closer to the 4-position of the oxidized phenol; therefore, the
intramolecular cyclization is much faster. The rate of reaction not only depends on the
placement of the olefin, but the conditions as well. It was found that spiro-annulation on
4-(2-alkenylphenyl)-phenols and the trimethylsilyl derivatives performed best in neutral
or mildly basic conditions. Furthermore, electrochemistry can be applied to substrates
containing acid or base-sensitive functional groups.

Scheme 1.9 The intramolecular anodic electrooxidative cyclization of phenols.
Mechanistically, there are two potential pathways annulation can occur within the
biphenyl substrate. The spiroannulation of 67 could be achieved by reaction of the
alkene with the phenoxonium intermediate.

Trapping of the carbocation 69 with

methanol completed the reaction. An alternative route could be a one electron loss from
the substrate followed by nucleophilic attack of the phenol on the oxidized styrene double
bond to generate radical 72. A second electron loss, quenching with methanol, and
finally dehydrogenation generates the spiro-fused 70 (Scheme 1.10).

13

Scheme 1.10 Mechanism of Spiroannulated phenol.

Routes to Oxaspirocycles
Application of Electroxidative Cyclizations
The use of electroxidative cyclization (EOC) has been a useful tool in the
synthesis of an array of small molecules. Many five, six, and seven-membered
cyclizations have been easily achieved for some of the more complex bioactive motifs.
Within the past several years there has been an increase of publications involving
electrochemical methodology, especially en route to some of these more complex natural
products. Researchers in these groups have developed efficient routes to a variety of
uniquely designed products found in nature including oxaspirocyclic compounds.
Although it is far from being a routine technique, electrochemical reactions have
gained a lot of interest within the organic synthesis community. This experimental
procedure usually can be identified as a last resort method once all other options have
been attempted.

Many researchers have found electrolysis to be straightforward,
14

environmentally friendly, and a quick path to some very interesting organic compounds.
These reactions can be either oxidations or reductions with the reactions being comprised
of the substrate, electrodes, electrolyte, solvent, and various additives.

EOCs are

tolerable of most functional groups and are applied to the synthesis of complex natural
products. They follow the general principle of radical-cation formation via
electroxidation, followed by an intramolecular trapping of a nucleophile that takes place
in organic solvents such as methanol and 2-propanol; these protic solvents in turn attack
the substrates nucleophilically due to the reactions taking place at the surface of the
electrodes.
Bernhardt et al. displayed that a direct approach to the 2-oxaspiro[4.5]decan-1one structural motif can be constructed by 6-π electrocyclization.10 Previously it had
been observed that the most ideal way to form spiro 74 was through the Diels-Alder
reaction of the lactone and a given reactive diene. A late-stage cyclization of the sixmembered ring is an unusual approach, but it proved to be a successful pathway to spirofused lactone 76 using the appended cyclohexene ring 75 (Scheme 1.11).

Scheme 1.11 Electrocyclization to the 2-oxospiro[4.5]decan-1-one structural motif.
15

Olefin Metathesis Reaction
The olefin metathesis was initially discovered in the mid-1950s and has been a
reliable resource to redistribute carbon-carbon double bonds in organic synthesis. There
was not always the availability of an effective catalyst until the 1980’s. Some major
issues with these earlier reactive catalysts are their sensitivity to oxygen and moisture in
the air in addition to having poor functional group tolerance. It was not until the
development of the ruthenium-based catalyst did they overcome these issues. Ruthenium
catalyst reacted preferentially with olefins in the presence of aldehydes, amides, alcohols,
and even carboxylic acids. The most recognized are the Grubbs 1st and 2nd generation
catalysts 77 and 78, which led to an eruption in olefin metathesis chemistry in the
synthetic world (Figure 1.3). They have been utilized in a variety of reactions such as
ring opening metathesis polymerization (ROMP), ring-closing metathesis (RCM), cross
metathesis (CM), ring-opening metathesis/cross metathesis (ROM/CM), and even tandem
reactions.

Figure 1.3 Ruthenium-based catalysts for metathesis
In 1999, Harrity and co-workers demonstrated an efficient way for the preparation
of functionalized spirocyclic systems using Grubbs’s 1st generation catalyst.11 The spirocompounds were made under mild reaction conditions. Oxaspiro 80 was assembled
using a tandem ring closing metathesis reaction on tetraalkene 79 (Scheme 1.12).
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Although it was found the 5-membered ring formation was dominant, there was a 7membered ring closure observed as well. The selectivity of the tandem metathesis can be
controlled by the amount of catalyst introduced into the environment. The oxaspiro 82
decomposed rapidly upon treatment with catalytic TsOH at ambient temperatures. Acid
catalyzed techniques were found to be harmful to the functionalized [4.4]-spiroacetals,
hence they were subjected to a neutral metal catalyzed cyclization condition for
completion.

Scheme 1.12 Tandem ring-closing metathesis (RCM) of tetraalkenes
Palladium Catalyzed Reactions towards Spiro-fused Furans
Bäckvall et al. explored the use of palladium as a means to form oxaspiro
compounds.12,13 Over the years this research group has focused on an approach to control
17

the stereochemistry for either cis or trans 1,4-addition across 1,3-diene double bonds.
Studies on the alcohols 87 and 91 have been an excellent template for palladiumcatalyzed oxidations due to the competing factors present in the cyclohexadiene ring.
Within these compounds lies the possibility of aromatization and/or Diels-Alder addition
to the existing diene. The presence of a base, such as lithium carbonate, has shown to
help expedite the intramolecular cyclization while a slow addition of the oxidant
benzoquinone suppresses aromatization of the starting material (Scheme 1.13).
Stereochemistry of the final oxaspiro product was heavily influenced by the salt added to
the system. This route has led to the construction of flexible spiro-fused furano building
blocks leading to the natural product theaspirone 90.

Scheme 1.13 The oxaspirocyclization of conjugated dienes via palladium-catalyzed
oxidations.

A different approach to the aforementioned theaspirone family of spiroethers was
investigated in 2000. Realizing other intramolecular oxaspirocyclizations already exist,
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Young and co-workers employ the assistance of Amberlyst-15 as an alternative catalyst
to the previously published technique with a palladium-catalyst.14 Young et al. have
reported a sufficient step by step route with secondary allylic alcohol 96. Treatment of
the allylic alcohols with the Amberlyst-15-catalyst proceeds through SN2 annulations to
produce 1-oxaspiro[4.4]non-6-enes 97 (Scheme 1.14). Limitations have been observed
with the spirocyclization of tertiary allylic alcohols because 1-oxaspiro[4.4]non-6-ene
and 6-oxaspiro[4.5]dec-1-ene systems allylic cannot be derived by treating the
corresponding 2-cyclopentenone with methyl lithium. After five steps theaspirone 98 has
been constructed in good yield at 67% using SN2 oxaspirocyclizations.

Scheme 1.14 The oxaspirocyclization of sterically hindered allylic alcohols toward
theaspirone

Robinson Annelation toward Spirofused Pyrans
Pfalz and co-workers were able to successfully expand upon the synthesis of
oxaspirocyclic compounds leading to pyran derivatives.15 The spiro-fused pyran 103 was
obtained via Robinson annelation upon treatment of 4-carboxaldehyde 102 with methyl
vinyl ketone and removal of the double bond by catalytic hydrogenation (Scheme 1.15).
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This method has been useful for a variety of heterocyclic compounds leading to a diverse
group of 3-heterospiro[5.5]undecan-9-ones. A novel method to increase the yield of the
starting aldehyde 102 is currently in the works by this group.

Scheme 1.15 Preparation of 3-Heterospiro[5.5]undecan-9-one from tetrahydropyran.

Natural Products and Targets
Within our group we have focused our research efforts on the synthesis of small
molecules derived from natural materials that exhibit biological activity. The motivation
for making these molecules have led to the following: 1) development of new methods
starting with oxabicyclic ring systems to produce building blocks for total synthesis 2)
innovative ways to form complex fused ring systems and analog library from natural
products previously synthesized within our research group, and 3) combination of
traditional and nontraditional ring annulations toward heterocyclic compounds.

Our

inspiration for these novel routes has been attributed to the natural products phelligridin
G 104 and platensimycin 105 (Figure 1.4). The overall structural framework and
important biological activity (antioxidant and antibacterial) have made these compounds
attractive targets for our research group. As medicinal chemists, it is our goal to use our
training as synthetic chemists to design new compounds in order to study their
bioactivity.
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Figure 1.4 Natural Product Targets

Antioxidants in Drug Discovery
Many scientific experts in the field of free radical and antioxidant biology have
seemingly joined the effort, pioneered by preventive medicine practitioners, to stimulate
disease prevention and health promotion research. Antioxidants are molecules capable of
inhibiting the oxidation of other molecules. Oxygen-derived free radicals have been
identified as the source to the pathology of more than 100 diseases.16 These free radicals
can be highly reactive and toxic causing oxidative stress in the human body. Controlling
these chemical reactions in the body can prevent the development of unwanted free
radicals, which can initiate chain reactions leading to cell damage or apoptosis. This
phenomenon contributes to the development of a wide variety of diseases from
Alzheimer’s disease, Parkinson’s, rheumatoid arthritis, cancer, and the pathologies
caused by diabetes. Currently, there are only a few drugs approved by the FDA used to
treat these diseases.

Memantine (Namenda) is an n-methyl-D-aspartate (NMDA)

receptor agonist used in the treatment of Alzheimer’s by regulating the activity of
glutamate.17 Succinobucol, a newly synthesized antioxidant, has shown promise in the
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prevention and treatment of diabetes.18 Doxorubicin (Adriamycin) is a drug administered
intravenously used to treat a variety of carcinomas during chemotherapy.19
Research over the past twenty years has led to the notion that antioxidant nutrients
are significantly associated with disease prevention (i.e. cardiovascular and
cerebrovascular disease, various carcinomas and age related disorders).16 Some of the
more familiar antioxidants include vitamins, vitamin-forming compounds such as
carotenoids, or manufactured in dietary supplements.20,21 Synthetic antioxidants are an
area of research actively being pursued to find new and more efficient ways to enhance
antioxidant defenses. Scavenging of these free radicals can occur in the intestines, brain,
muscles, or tissues by the addition of these potential synthetic antioxidants. Being that
small molecule therapeutics derived from synthetic antioxidants requires long-term
administration and exhibit adverse side-effects, chemists continue the investigation of
novel agents for these diseases.
Phelligridin G
A significant amount of the medicines today are derived from natural products
that can be found in various plant species throughout nature as well as algae or fungi.
Natural products are a significant source of new drugs, especially in the anticancer and
antihypertensive therapeutic areas.22 There is now increasing evidence with experimental
animals that regular feeding of powdered medicinal mushrooms can have a cancer
prevention effect, demonstrating both high antitumor activity and restriction of tumor
metastasis.23 A potent family of medicinal fungi are the polysaccharides derived from
Phellinus igniarius and Agrocybe cylindracea.24
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Secondary metabolites produced by the fruiting bodies of mushrooms frequently
display a variety of unique structures and interesting biological activities. Phelligridins
D, E, and G are derived from the fruiting body of the fungus P. igniarius, a member of
the Polyporaceae family (Figure 1.5). The highly oxygenated fungal metabolites are
indigenous of the Dandong district in Liaoning province, China. The fruiting body of P.
igniarius has been long used for the treatment of fester, bellyache and bloody gonorrhea
as a traditional Chinese medicine.25 Of these three derivatives phelligridin G has shown
the better antioxidant activity inhibiting rat liver microsomal lipid peroxidation
(IC50=3.86µM), and moderate selective cytotoxic activities against human ovarian cancer
cell line (A2780) and colon cancer cell lines (HCT-8).26 Based on the potential of
phelligridin G as an anti-cancer agent along with its unique and synthetically challenging
spirofused-furanone, we set out to develop a rapid and efficient synthetic route to the core
domain of the natural product.

Figure 3.5 Structural Derivatives of Phellinus igniarius
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Antibacterial Drug Development
Over the past decade, there has been an increased need for new antibacterial
agents due to the resistance of existing therapeutics. Fatty acid synthase by bacterial type
II fatty acid synthase (FASII) can be carried out by a series of discrete enzymes. There
are important structural differences in the enzymes of bacterial systems that allow the
development of potential inhibitors to target these systems. Most of the FASII enzymes
are essential for bacterial viability which makes them suitable targets for antibacterial
drug discovery. There have been a number of scientific reviews published discussing the
inhibition of bacterial fatty acid synthesis.27 Natural products are known to target the
elongation condensing enzymes step in the fatty acid biosynthesis pathway which makes
them desirable targets for therapeutics.

Some of these natural compounds include

cerulenin, thiolactomycin (TLM), phomallenic acids, platensimycin, and most recently
fasamycin.
Over two decades ago they identified the first inhibitor cerulenin, which
selectively targets FabF/FabB and covalently bonds to the cysteine in the active site of
the enzyme. Cerulenin is an antifungal antibiotic with minimal inhibitory concentration
(MIC) of 64-128µg/mL and inhibitory concentration (IC50) of 1.5µg/mL against S.
aureus.28 During this time thiolactimycin was also discovered and found to be a selective
dual inhibitor of FabH and FabF/B while binding to malonate in the active site. This
reversible inhibitor showed MIC and IC50 values of 64-128 µg/mL and 13 µg/mL
respectively against the gram positive S. aureus. In 2002, Townsend and co-workers
developed an asymmetric route towards this modest antibacterial agent.29
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In their

synthetic route they used amino acids as chiral building blocks to assemble the natural
product thiolactone.
Studies on phomallenic acids A, B, and C showed good antibacterial and FASII
activities against S. aureus, H. influenza, B. subtilis, and E.coli. Of the three analogs
phomallenic C exhibited the most potent activity against these strains with significantly
lower IC50 values than A or B. Utilizing a whole-cell screening approach such as those
performed by Young et al. proved that the inhibition of fatty acid synthesis enzymes is
responsible for inhibiting growth of bacteria leading to the discovery of potential
antibacterial drugs.28
Platensimycin: Background
Scientist at Merck and Co., Inc. discovered two promising natural products
platensimycin and platencin produced by Steptomyces platensis in 2006. These novel
antibiotics showed promising antibacterial activity along with no observed toxicity.
Platensimycin is effective against methicillin-resistant Staphylococcus aureus and
vancomycin-resistant enterococci. With such promise as a useful drug against antibioticresistant gram-positive bacterial pathogens, there is a concern with its pharmacokinetic
properties. Platensimycin inhibits the elongation-condensing enzyme FabF, but platencin
can be seen as a dual inhibitor of FabF and FabH. MIC values of platensimycin against
gram-positive bacteria are some of the best observed at 0.1-0.32µg/mL.30 Comparison
between the two derivatives found that platensimycin exhibited poor activity against
FabH, while platencin was 15 fold less active against the Fab F enzyme. Both derivatives
provide a solution to fighting antibiotic-resistant bacteria, but due to poor
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pharmacokinetics reported by researchers they have yet to enter clinical trials. This has
led to the rationale and increased interest for analog development via modifications of its
molecular structure. Platensimycin has two distinct structural domains: the hydrophilic
dihydroxybenzoic acid and the hydrophobic tetracyclic enone moieties linked together by
an amide bond (Figure 1.4).

Survey of Structural Analogues
Within the past 5 years there have been a number of research groups that have
synthesized structural analogs of the parent compound platensimycin. In 2009, scientist
at Merck developed an analog program based on the alteration of the tetracyclic ketolide
domain. While performing initial studies based on the structure-activity relationship,
they found that chemically modifying the enone moiety could have a major impact on the
potency of molecule. They were able to develop a library of nine different analogs that
inhibit the FabF enzyme as well as show some antibacterial activity.
Researchers at Merck Laboratories created an extensive analog program to help
guide their future structural designs based upon structure-activity relationship (SAR) and
the pharmacophore of platensimycin.31 Shen and co-workers believed that the poor
pharmacokinetics of platensimycin is possibly due to the enone moiety of the compound.
The natural products high clearance in vivo can be attributed to this component acting as
an electrophile; therefore, modifying this group can potentially reduce the undesirable
properties without reducing the antibacterial activity. The first set of analogs 108 a-d
required saturation of the double bond of the six-membered enone ring (Scheme 1.16).
The olefin did not show any direct interactions with the FabF enzyme; however, they
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noticed a 4-8 fold loss of antibacterial activity against the wild type S. aureus. The
reason for such a loss is a direct result of the minor repositioning of the ketone as well as
the benzoic acid moiety which occurs because the platensimycin changes from the boat
conformation to the chair conformation with the absence of the double bond in the
cyclohexenone ring. The binding pocket of platensimycin is quite rigid and cannot
contain substantial conformational changes. A cyclopropyl group was added via the
Corey-Chaykovsky cyclopropanation to give cyclopropyl analog 108d which proved to
be 4 fold more active than the saturated compound 108a.

Scheme 1.16 Synthetic route towards tetracyclic derivatives
S. aureus MIC values
(µg/mL)

IC50 sa FASII (µg/mL)

105

0.5

0.5

108a

2

2

108b

4

13

108c

4

4

R

Compound
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108d

1

9.5

108e

16

10.5

108f

>64

75.3

108g

4

2.4

108h

>64

73.6

108i

>64

>200

A way to replace the electrophilic enone was by developing a series of fused heterocyclic
analogs. They utilized pyrazole and isoxazole hoping the heteroatoms could mimic the
missing enone carbonyl oxygen, while maintaining the sp2 character of the ketone αcarbon in the natural product. Generation of heterocycles 108e and 108f resulted in
analogs with much weaker activity. The presence of a heteroatom to replace the α-carbon
of the enone was also investigated by this research group. Preparation of lactone 108h
and lactam 108i were achieved, yet exhibiting the worse activity of all the analogs
synthesized.
It was found through SAR that the conformation of the enone moiety is very important in
the positioning of the ketone carbonyl group to maximize its interaction with A309 of
FabF. Minimal conformational changes such as in analog 108b by simple methylation of
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the β-position of the enone proved to be the most active in the FabF enzyme of all the
compounds in the library. Those analogs such as 108d and 108g having a similar
conformation to platensimycin in addition to the presence of the ketone group seemed to
be more favorable as future analog designs.
Nicolaou and co-workers performed some of the first reported synthetic strategies
in analog development as well as the SAR data of platensimycin by implementing
varying degrees of molecular complexity.32 Based upon X-ray crystallographic data of
platensimycin in complex with a mutant version of FabF enzyme showed two distinct
domains for binding within the target. These findings have led the Nicolaou group to
create two series of analogues by modifying both the hydrophilic benzoic acid domain
and lipophilic cage domain (Figure 1.6). Changes to the polar aromatic group can assist
in determining the importance of the substitution pattern for biological activity leading to
analogue series I. Secondly the analogue II series probed adjustments made to the
tetracyclic cage moiety to note any biological changes.

Figure 1.6 The two distinctive domains of platensimycin
The synthesis of analogue series I required the use of platensic acid 109 which
was the key intermediate toward their published asymmetric approach to platensimycin.33
The aniline derivatives were obtained through a late-stage divergence from commercially
available carboxylic acids. Coupling of platensic acid 109 with the synthesized amines
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were accomplished by a HATU-mediated amide coupling (Scheme 1.17). The results of
these structural modifications negatively impacted the biological profile of the natural
product. The benzoic acid analogue showing the best MIC values against MRSA was
platensic acid 109 at 37-58µm/mL.

Scheme 1.17 Synthesis of aniline derivatives
Analogue series II was more strategic due to the fact they wanted to assemble
complex cage mimics, in addition structurally similar to the parent natural product (Table
1.1).

A cyclohexenone derivative was prepared sequentially by allylation and

methylation in the presence of base, a chemoselective cross-metathesis to give
corresponding E/Z isomers of pinacol boronates which were subjected to oxidative
cleavage to give an aldehyde. A key Pinnick oxidation of the carbonyl led to racemates
of methyl esters that could be easily separated using a chiral column. Final amide
coupling with the aniline fragment and deprotections gave the cage analogues 114-117.
Surprisingly, this derivative exhibited some antibiotic activity without regards to the
lower amount of structural complexity with MIC values of 3.5-4.3µg/mL against MRSA.
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Table 1.1
Compound

MRSA

VREF

105

1.1-2.2

1.1-1.2

114

1.3-1.8

1.3-1.8

115

3.5-4.4

6.5-8.6

116

8.0-10

>80

117

17-20

>85

110

>85

>85

111

>85

>85

112

>82

>82

113

>73

>73

109

37-58

>58
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Within this library of compounds they furnished nitrogen containing heteroatom
derivatives 119 and 121 (Figure 1.7).

Unfortunately, these compounds showed the

poorest MIC values at >88 and >86 respectively. The four most active members of
analogue series II are compounds 105, 114, 115 and 116 falling between
1.1µm/mL<MICMRSA<10µm/mL. In the tetracyclic cage certain modifications can be
tolerated without major effects on biological activity. The data reported has served as a
guideline for future design and synthesis of any analog program of platensimycin to
create more potent antibacterial agents.

Figure 1.7 Derivatives containing nitrogen heteroatom
Sintim and co-workers have developed a route to the tetracyclic ketolide of
platensimycin using a unique synthetic route.34 Using this method have led to their
investigation of simpler analogues of the natural product. These analogues include the
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oxazinidinyl platensimycin 122, its methyl ester analogue 123, and a simpler oxazinidinyl
analogue 124 (Figure 1.8).

Figure 1.8 Platensimycin and novel analogues containing two heteroatoms
The path to oxazinidinyl 122 was achieved through a successful synthesis of tricycle 133
starting with bis-alkene 126. Employing a regioselective epoxidation to intermediate 128
is a key step to the overall route towards tricycle 132 (Scheme1.18).

They have

fashioned a novel strategy using dynamic ring-closing metathesis and nucleophilic
addition to a ketone as well as epoxide ring opening to obtain the tricyclic core of
platensimycin. Following this pathway the Sintim group made other polycyclic motifs
and found its biological data. The most potent analogue oxazinidinyl platensimycin 122
showed a minimal inhibitory concentration (MIC) of 90µg/mL for the bacterial strains
tested. Analysis of the methyl ester analogue 123 and the platensimycin analogue with
the simpler core structure 124 exhibited values greater than 512µg/mL. The MIC values
observed further leads to the fact that any modification to the ketolide can have a major
affect on antibiotic potency indicating how important it is to have the enone present in the
molecule.
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Scheme 1.18 Total synthesis of oxazinidinyl platensimycin

A method exploiting the organopalladium cross-coupling reactions were
implemented by McNulty and co-workers towards sulfonamide analogs.35 Installation of
a carboxylic group to nitroresorcinol halide 137 was facilitated by palladium complexed
with 1,3,5,7-tetra-methyl-2,4,8-trioxa-6-phenyl-6-phospha-adamantane (Pd(OAc)2/PAPh). Reduction of the nitroester 138 followed by subsequent conversion to sulfonamide
ester 140 led to their series of lipophilic aryl analogues in good yields (Scheme 1.19).
This route was used to replace the bulky tetracyclic core of platensimycin with the
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sulfonamide moiety, which can be found in a variety of antibiotics. In six sequential steps
they have created a set of novel analogues that are currently undergoing biological
evaluations.

Scheme 1.19 Palladium-mediated carbonylation toward sulfonamide analogues
There has been reported by Lee and co-workers that they have synthesized two
analogues more potent than platensimycin.36 An efficient and concise route to the parent
compound has been achieved via intramolecular dipolar cycloaddition of a carbon ylide
to produce intermediate 142. Further elaboration of this tricyclic construct has led to the
derivation of a wide variety of easily accessible analogues (Scheme 1.20). In vitro
bioassay studies with the aforementioned compounds verified the substitution of the 15methyl group did little to enhance antibacterial activity of the compound. Interestingly,
they found analogues 7-phenylplatensimycin 144g and 11-methyl-7-phenylplatensimycin
144h displayed higher activity than platensimycin against MRSA.
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Scheme 1.20 Carbonyl ylide cycloaddition route to a series of more potent analogues
With so many research groups generating novel analogues centered only around
changing the polycyclic ketolide, Manallack and co-workers have recently reported a
series of simplified molecular mimics of platensimycin.37 This library of compounds
underwent modifications to both the benzoic acid moiety and tetracyclic enone of the
parent compound. These changes still capture the key binding elements observed in
platensimycin within the FabF active site; however, the new compounds exhibit reduced
flexibility and molecular weight.

The series of 2-hydroxybenzoic acid derivatives

designed directly linked the aromatic group to a set of cyclic aliphatic structures. SAR
studies were performed on a variety of polycyclic cage-like moieties made by this group
(Table 1.2). Additionally, other compounds were synthesized that simplified the highly
substituted benzoic acid ring to a 3-amino-2-hydroxybenzoic acid.

Based on these

studies it was found that simplification of platensimycin reduced biological activity. It
was imperative that the groups required for activity are the 4-hydroxy group along with
those necessary for hydrogen bonding to residues close to the binding pocket.
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Scheme 1.21 Strategy towards semi-rigid compounds
Table 1.2

Compound
147a
147b

OH
H

0
0

148a
148b

OH
H

20
0

149a
149b

OH
H

0
0

150a
150b

OH
H

8
0

151a
151b

OH
H

0
0

152a
152b

OH
H

0
21

153a
153b

OH
H

38
14

154a
154b

OH
H

10
10

R1

R2

MRSA (10 ug/disc)
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Summary and Conclusion
The connections between natural bioactive molecules and medicines have been
known for thousands of years. With increasing pathogen resistance to some existing
therapeutic agents plus the evolution of new diseases, the continuous efforts of
researchers has been focused on novel drug candidates. Medicinal chemists are
designing novel synthetic routes furthermore enhancing the efficacy and potency of
natural products through analog development. A wide range of chemical reactions have
been responsible for the syntheses of these intricate scaffolds from their simpler
counterparts. Oxabicyclic synthons are valuable intermediates derived from the DielsAlder reaction to incorporate molecular complexity observed in natural products.
Combining this reaction with metathesis reorganizations have been utilized quite often
for the formation of fused polycyclic and spirocyclic structures embedded in various
complex natural structures. Implementation of these two key reactions can help in our
routes towards our desired targets. Antioxidants have been probed due to their practical
application as a means to stabilize free radicals in the body which are responsible for
numerous diseases. Infectious disease remains a constant nuisance to humanity despite
the development of so many new antibiotics. The existing analogue programs for the
antibiotic platensimycin focused on changes to both regions of the molecule; however, it
is hypothesized that manipulation of the tetracyclic ketolide will have the greatest
influence on the bioactivity in the enzyme. Hence this lipophilic polycyclic domain has
been the key focal point of many researchers.
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CHAPTER 2
RESULTS/DISCUSSIONS
In this chapter we will discuss our investigation into the application of new
synthetic routes towards complex furan containing natural products. The first section
will describe the strategies towards phelligridin G using both electrochemical oxidation
of furyl substituted silyl enol ethers and behavior of oxabicyclic bridged ethers in the
presence of Grubbs’ olefin metathesis. The last section describes our route to novel
analogs of platensimycin using flexible ether-bridged synthons. Exploitation of this
molecular scaffold made it feasible to develop novel derivatives in a concise and direct
formal total synthesis.
Spirocyclic Core of Phelligridin G
Our retrosynthetic analysis targeted the core domain 104 comprised of the A, B
and C rings that contains the challenging 2-oxaspiro-[4.4]-octane unit (Scheme 1). We
have been interested for some time in developing furan-based methodologies for the
synthesis of polycyclic systems and felt that phelligridin G offered an excellent target to
evaluate two strategies we have pursued. In one path, the presence of the spiro-fused 3furanone makes it an attractive target for an electrochemical annulation strategy through
oxidative cyclization of 156.

We have worked extensively with furan-terminated

electrochemical oxidative cyclizations and this method has been successful in the
formation of 5-, 6-, and 7-membered carbocycles.1–4 In a parallel approach to the anodic
oxidation, a sequential furan Diels-Alder reaction to give 155, followed by a ring opening
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metathesis/ring closing metathesis (ROM/RCM) process could also deliver the target
intermediate, a strategy we have recently employed in an approach to cyclopamine.5
Exploration of both strategies would rely on the same two commercially available
building blocks 158 and 159.

Scheme 2.1 Retrosynthetic Analysis of Phelligridin G

Currently there are no published syntheses of any member of the phelligridin family of
natural compounds.

Anodic Oxidation of Silyl Enol Ethers
The goal of our early studies was to investigate the behavior of silyl enol ethers
tethered to 2-phenylfuran substrates. Initial evaluation of the spiro-fused 3-furanone 155
made it an interesting target through a nontraditional ring annulation methodology.
Electrochemical methods have usually been examined as a last resort in the oxidative and
43

reductive conversions in organic chemistry. Previous studies in our research group have
allowed us to utilize electrochemical oxidations because this particular route is
uncomplicated, environmentally friendly, and a quick path to some very interesting
organic compounds.2–4,6 A variety of ring closures have been successfully achieved
including five-, six-, and seven-membered carbocycles present in many biologically
active motifs.

For phelligridin G, we have synthesized a series of enol ether

intermediates to attempt a two-step, conjugate addition/anodic oxidation sequence to gain
access to the annulated furan moiety. The commercially available starting materials 2furanboronic acid 158 and 3,4-dimethoxy-bromobenzaldehyde 159 were united through
standard Suzuki cross-coupling with bis(triphenylphosphine)palladium(II) dichloride to
produce the 2-phenyl-furan derivative 160 in good yield (Scheme 2.2). The aldehyde was
homologated with t-butyldimethylsilyl cyanide, followed by reduction of the nitrile group
in the presence of DIBAL-H to give the protected α-hydroxyaldehyde after hydrolysis
with dilute sulfuric acid.

The α,β-unsaturated aldehyde underwent smooth Wittig

olefination to deliver enol ether intermediate 163.
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Scheme 2.2 Electrooxidative cyclization attempt to the spirocyclic core of phelligridin G

Due to its ease of reactivity, the aldehyde functional group was our target location
for chemical transformations in order to generate a series of enol ether cyclization
precursors (Scheme 2.3). The formerly synthesized 2-furylbenzaldehyde 160 was
olefinated under standard Wittig conditions with 1-triphenylphosporanylidene-2propanone in the presence of nBuLi base. After methyl ketone 165a was generated and
purified, the formation of our electron rich silyl enol ether intermediate was attempted.
Originally our efforts were focused towards conjugate reduction of the carbonyl
derivative, so we began with the commonly used copper hydride ligand complex known
as Stryker’s reagent.7 In addition, we contemplated using a copper (I) source in
conjunction with methyl Grignard to promote a 1,4 addition to the methyl ketone.
Surprisingly, generation of the enolate anion failed in this particular system only to
surrender starting enone which made trapping the trimethylsilyl cation impossible.
Finally, 165b was obtained after successful saturation of the double bond with
Wilkinson’s rhodium catalyst and enolate trapping with triethylsilane in good yield.8
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This compound was prepared for electrooxidative cyclization without any further
purification.
Most reported oxidative cyclization strategies have been performed using electron
rich alkenes as a means to generate the radical-cations, however, we wanted to
investigate the oxidation potential of an appended alkyne to the substrate (Scheme 2.3).
Our synthetic approach started with the lithiation of the ethoxyacetylene reagent at low
temperature. Aldehyde 160 was placed in the cold solution dropwise along with HMPA
to catalyze the homologation. The secondary alcohol 166a was obtained and protected
with TBSCl forming silyl ethynyl ether 166b. The crude product was readily available
for oxidative cyclization experimentations.
Moeller et al. have found highly functionalized silyloxy enol ethers decompose
during electrochemical oxidations in certain substrates due to instability. To avoid this
issue 1,3-dithiane was added to the aldehyde and found to be a suitable radical-cation
replacement for ring annulations.9,10 Biphenyl 162 was added to a solution of lithiated
dithiane at -78°C then slowly warmed up to room temperature until complete
consumption of starting material (Scheme 2.3). This reaction was monitored by TLC
resulting in a very clean reaction to give thioether 167. The aforementioned cyclization
precursors did not undergo ring annulation during electrolysis.
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Scheme 2.3 Routes leading toward enol ether intermediates

Being that the initial electron loss in the cyclization precursor is unknown, we have
developed electronically diverse intermediates 163-167 accessed through the aldehyde
moiety (Figure 2.1). These substrates were studied by cyclic voltammetry to resolve this
issue. Unfortunately, all attempts to produce the spiro-fused product through anodic
oxidation failed, producing only complex mixtures of products despite our earlier success
with similar sytems.11
Cyclic Voltammetry Studies
Cyclic voltammetry (CV) was used to determine the oxidation potential of the
intermediates 163, 164, 165b, 166b, and 167 (Figure 2.1). Both furan and enol ethers
have the ability to undergo electrochemical oxidations; therefore, these experiments
helped identify the initial site of oxidation under our reaction conditions. A mechanism
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can be developed from these studies to explain how ring annulation can occur within the
system. CV analysis shows which substrate has the lowest oxidation potential; this
information will indicate the initial loss of electron.

The electrochemical oxidation

cyclizations attempted were constant current experiments, meaning that potential at the
surface rises until the first oxidation potential is reached. Hence if the silyl enol ether
oxidation potential is lower than the 2-phenylfuran, it can be concluded that the silyl enol
ether is the preliminary site of oxidation. Due to the high functionality of our substrates,
it is possible to have multiple oxidation sites along with single electron transfer leading to
the formation of an alternate radical-cation.

Figure 2.1 Synthesized enol ether electrooxidative cyclization intermediates
The model studies show that the substrates tested exhibited an irreversible oxidation
wave pattern in the voltammogram. In previously published works by Sperry et al., it
was found that monoalkylated furan has an oxidation potential of 1.3V.2 Our parameters
for the experiment are dissolving the crude substrate in an “electrolyte” solution and
placed in a small glass cell. The environment must be oxygen free, so all reactions were
done in a glove box. The voltammogram was set at 200mV/s with continuous scanning
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until complete oxidation of the material. As a reference, ferrocene was added to the cell
along with the silyl enol ether substrates which is commonly used in most CV
experiments. The ferrocene shows a duck-like figure which indicates the compound
undergoes an immediate reduction after being fully oxidized making it reversible. This
duck shape is missing from the graph of the organic analytes, so they are designated
irreversible preventing any reduction once oxidation is complete (See Appendix B). As
the current is passed through compound 163, there were three bumps seen on the graph.
Each bump determines the location of primary electron loss in our given system by
adding 0.5mA of current. Initial electron loss occurred at the silyl enol ether at ~1.2V
with a second oxidation taking place on the furan at 1.3V (previously reported above by
Sperry et al.). The third and final oxidation site occurs at the methoxy oxygen group
appended to the alkene at 1.5V.

Further CV analysis showed that doubling the

concentration of analyte requires the current to be doubled to initiate loss of an electron
within the system. The oxidation potential of ether 165b and 166b showed two sites of
electron transfer for both compounds at 1.1V, 1.3V and 1.0V, 1.3V respectively. The
ethynl ether required ~1.1mA for electron loss while the triethylsilyl ether was increased
to ~3.5mA of current to facilitate oxidation. The addition of ferrocine to the analyte 163
acts as our reference to verify oxidation is irreversible once complete for our enol ether
intermediates. All three compounds proved to be irreversible, a key attribute of all
organic molecules due to the production of highly reactive intermediate radical-ions that
undergo further reaction upon formation.
Further oxidative studies with the above silyl enol ethers were attempted using the
traditional chemical oxidants cerium(IV)ammonium nitrate (CAN)12 and tris(449

bromophenyl)aminium hexachloroantimonate (BAHA)13 which are known to oxidize
electron-rich olefins, but also proved to be ineffective. Use of the BAHA reagent had
previously shown promise in the oxidation of silyl enol ether intermediates; however, this
alternative method required longer reaction times along with tedious workups. Despite
prior success with similar oxidative cyclization, we believe that the presence of additional
groups with low oxidation potentials such as the dimethoxyphenyl ring and a 2-aryl furan
leads to significant over oxidation and ultimate destruction of the starting material. The
failure to detect any appreciable cyclized material prompted us to explore the alternative
cycloaddition/metathesis approach to this class of compounds.

Domino Ring-Opening Metathesis/Ring-Closing Metathesis (ROM/RCM)
A competition study was performed to determine if the presence of additional EWG
(methoxy groups) played a role in the ability to hinder Diels-Alder adduct formation with
certain dienophiles. We examined the potential of two electronically diverse phenylfuran
scaffolds (Scheme 2.4).

Following a modified procedure, Suzuki palladium cross-

coupling of di- and tetra-substituted bromobenzaldehyde (159 and 168) to 2-furylboronic
acid 158 we obtained the 2-phenylfurans 160 and 169 in excellent yields.14

Scheme 2.4 Suzuki cross coupling of furan boronic acid
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The accessibility of the α,β-unsaturated carbonyl allows for easy functional
transformations that can lead to the desired annulated spiro-fused intermediate.
A survey has been conducted on some readily available dienophiles with 2phenylfuran substrates 160, 170, and 171. Each aldehyde was rapidly converted to the
styrylfuran using Wittig olefination at 0°C in the presence of n-butyllithium base in
appreciable yields. Cycloadduct formation is essential for a successful Grubbs’ ring
opening/ring closing metathesis response due to the increased ring strain of the system.
The results obtained have led us to find the most reliable dienophiles to move forward
with our spiro-annulation studies on the ether-bridged intermediates (Table 2.1). For all
the olefin containing compounds we obtained only starting material which is labeled as
NR in the table. The alkyne reagents showed a lot more promise; however, stirring 170
with the tosyl acetylene produced only starting material and reacting with the disubstituted arylfuran 171 gave unwanted side products.

Table 2.1 Diels-Alder reaction with 2-phenylfurans
Substrate
170

Dienophile

Temperature

Time

Yield (%)

40-80°C

5-7days

NR

25°C

5 days

NR

171

170
171
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170

60-80°C

5 days

NR

171

55°C

5 days

47%

170

40°C

24hrs

55%

170

40-50°C

3 days

NR

160

55°C

3days

68%

170

45%

170

160

45-55°C

3-5days

Decomposition

170

Toward Oxaspiro-furan Systems
The value of oxabicyclic building blocks for the preparation of five-membered
heterocycles has been appreciated for some time.15–17 Our synthesis of the spirocyclic
core of phelligridin G would be achieved in four steps starting with the previously
described furyl-benzaldehyde derivative 160 (Scheme 2.5).18 Olefination of the α,βunsaturated carbonyl with methyl triphenylphosphonium bromide in the presence of nbutyl lithium yielded styrylfuran 170. In order to obtain a suitable precursor for the
metathesis-driven bond reorganization, thermal cycloaddition to the furan via standard
Diels-Alder reaction was envisioned. Usually furan is a highly reactive diene; however,
this reactivity became highly attenuated in this system due to the presence of the aryl ring
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in the C2 position. It has been previously observed that 2-phenylfurans are poor dienes in
Diels-Alder cycloadditions as a direct result of their high π–conjugation, which is
destroyed upon formation of the cycloadduct, thus promoting rapid retro-Diels-Alder
reaction.19 We explored a series of structurally diverse dienophiles based upon
accessibility and reactivity rates to form the cycloaddition products.

Scheme 2.5 Synthesis of ABC spiroannulated core via Domino ROM/RCM metathesis

Observed in Table 2.1, we found that the sp2-type dienophiles such as nmethylmaleimide, cyanovinyl acetate, dimethyl fumarate and fumaryl chloride only
returned unchanged starting materials after days of continuous heating. Using more
reactive alkynes seemed promising as we had some success with treating substituted
furan scaffolds with acetylenic dienophiles in previous studies.5 However, with this 2phenylfuran there was no oxabicyclic ether formation observed at moderate temperatures
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with monofunctionalized alkynes such as tosyl acetylene or methyl propriolate.

At

higher temperatures, cycloaddition does occur but this is followed by a spontaneous ringopening/aromatization process to produce an undesired phenol. Pleasingly, use of a more
deactivated alkyne, dimethyl acetylenedicarboxylate (DMAD), under mild thermal
conditions (rt→40ºC) led to the desired adduct 174 in reasonable yield.

We also

examined the potential of aldehyde 160 to participate in the [4+2] cycloaddition. As
expected, condensation of aldehyde 160 with DMAD required higher temperatures
(55ºC) as well as longer reaction time owing to the presence of the electron-withdrawing
group which deactivates the furan ring system. Ultimately, this reaction did produce the
adduct 173 in ~50% isolated yield which could be taken on to 174 by olefination.
Furthermore, small amounts of Michael product 172 occurred as a byproduct. With the
key oxabridged intermediate in hand, we were able to attempt the key metathesis
reaction. The oxabicyclo adduct 174 undergoes a ring opening/ring closing (ROM/RCM)
domino type metathesis using Grubbs 2nd generation catalyst 78 to form spiro compound
175 as a single diastereomer (1H and
phelligridin G.

13

C-NMR) that contains the core structure of

The release of ring-strain in the bridged bicyclic compound is an

important driving force in these types of reactions and have been increasingly used to
generate complex natural products.5,20–23
Toward Oxaspiro-pyran Systems
In our desire to expand this utility of this methodology, we looked at the highly
reactive perhalogenated cyclopropenes as cycloaddition partners (Scheme 2.6). With the
assistance of these compounds, we have been able to develop building blocks leading to
the synthesis of several natural products.24,25
54

It was felt that the cycloaddition of

perhalocyclopropenes would be more efficient as the initial cycloadduct spontaneously
rearranges to the ring-expanded system thus preventing the retro-Diels-Alder reaction
from taking place.

Oxabicyclic[3.2.1]octane 176 was easily prepared in a one-pot

sequence that involved heating 160 and tetrachlorocyclopropene 6a at 55ºC for 4 days,
followed by olefination to give 176 without benefit of further purification. Compound
170 under similar reaction conditions was much less reactive as the alkene seemed to
hinder the cycloadduct formation with this particular dienophile.

Scheme 2.6 Expansion of the C-ring of phelligridin G core to form spiro-fused pyran

The strained ether-bridged seven-membered ring likely undergoes a ring opening of
the endocyclic double bond followed by closure with the terminal olefin to form the B
ring of the spiro-fused product. For oxabicyclic[3.2.1]octane 177, the GII catalyst 78
was also optimal but heating of the mixture was unnecessary in this system and produce
the highly functionalized spiro-pyran 178 in moderate overall yield.18
Efforts Leading to Novel Analogues of Platensimycin
We have recently developed a novel route to the natural product (+/-)-platensimycin
utilizing a highly substituted furan and tetrabromocyclopropene (TBCP) to form a
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flexible oxabicyclic moiety.24 The key feature of this synthetic pathway is that it allows
for a late stage intramolecular γ-alkylation to form the hydrophobic tetracyclic ketolide
precursor to the parent compound. According to work performed by researchers at
Merck Laboratory, they have developed numerous analogs based upon the alteration of
the hydrophobic caged region of platensimycin.26 Retrosynthetic analysis focusing on the
manipulation of the lipophilic moiety will lead to two distinct series of analogues
(Scheme 2.7). The first series will analyze ring constriction of the C-ring from a 6membered cyclohexenone to the 5-membered cyclopentenone. A second series will
require the deletion of the C-ring leading to some simplified acyclic mimics. Both sets of
derivatives can be generated through the bicyclic intermediate 186, which are prepared
by a thermal cycloaddition of TBCP and 2,3-disubstituted furan 179. Of the various
analogues discussed in Chapter 1, our motifs are structurally unique based on the original
strategy developed within our research group. These changes to the hydrophobic cage
should influence the antibacterial activity.
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Scheme 2.7 Retrosynthesis of Platensimycin leading to new analogue systems

In

our

approach

furan

179

was

reacted

with

the

dienophile

tetrabromocyclopropene (TBCP) to afford a mixture of tetrabromides 180a and 180b.
Hydrolysis with silver nitrate and acid promoted deprotection gave a 4:1 mixture of
regioisomers 183 and 184 in about 96% yield (Scheme 2.8). It has been observed that the
presence of the methyl substituent at the bridgehead sterically hinders the attack of the
water molecule on intermediate 182 leading to the major enone 183. During this step
nitric acid is formed in the reaction media causing loss of the silyloxy group leading to
unprotected alcohols that were easily separable via chromatography.
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Scheme 2.8 Synthesis toward dibromoenone intermediates
Protection of the major primary alcohol yielded 185, which simultaneously underwent
catalytic hydrogenation and debromination with Pd/C under H2 atmosphere in the
presence of triethylamine base; moreover, further saturation of the alkene at C11-C12
occurred.

A single diastereomer of keto silyl ether 186 was obtained due to the

preference for exo addition to the bridged oxabicyclic ring system which establishes the
three contiguous centers found in the natural product. Using the keto silyl ether 186, we
have developed two model studies to test the feasibility of the key intramolecular
alkylation reaction (Scheme 2.9). The products attained during ring closure led to the
inspiration of our distinctive synthetic routes toward an analogue program centered
around the caged domain of platensimycin. Ketone 186 was alkylated with allyl iodide in
the presence of LiHMDS base. Being that the reaction is influenced kinetically, the
temperature had to remain relatively low to prevent unwanted dialkylated product
formation. Controlling the temperature and holding it between -78°C and -10°C, the
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desired monoalkylated ketone was the major product 187 obtained; however, dialkylated
product was always observed if temperatures rose to room temperature while stirring.
Another determining factor that played a key role in our alkylation was the base
selection; although KHMDS improved the rate of reaction it gave mostly dialkylated
ketone. The simple tosylated ketone 188 was obtained by cleavage of the silyl protecting
group with concentrated acid, HF.pyridine, followed by activation of the primary alcohol
with tosyl chloride, DMAP, and triethylamine.

Scheme 2.9
Using the oxabicyclic intermediate in our first model system, we exposed the alkylated
silyl ether 187 to an acid solution of hydrogen fluoride in pyridine followed by tosylation
to give activated 189. The allyl ketone 189 was treated with tBuOK in tBuOH solution at
ambient temperature to give way to the desired caged ether-bridged cycloadduct 190. A
key difference in this base promoted intramolecular displacement from our original
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published sequence is the seco cage formation takes place earlier in the reaction scheme
as opposed to being the concluding step of the synthetic route. A modified Wacker
oxidation procedure offered a route to install the subsequent ketone necessary for a
cyclocondensation.27–29 The terminal olefin 190 was added to a mixture of copper (II)
acetate and palladium dichloride in THF under an oxygen atmosphere for 24h. Standard
conditions of this oxidation method commonly utilized a stoichiometric amount of CuCl.
It has been shown that replacing CuCl with Cu(OAc)2 suppressed the acidic hydrolysis of
the ketone during the catalytic cycle. Robertson and co-workers found these reaction
conditions to be the most realiable.30 Continuous bubbling of oxygen into the solution
yields the desired methyl ketone 191. Emergence of the α,β-unsaturated carbonyl via
oxidation of the vinyl group led to the essential diketone for an aldol condensation
pathway to generate polycyclic ring structures.27 Dropwise addition of tBuOK/tBuOH
base facilitated the formation of the cyclopentenone C-ring 192 in moderate yields.
Completion of this novel analogous structure was achieved upon hydrogenation of the
C4-C9 double bond.

Due to the facial selectivity of the cyclopentenone ring, we

attempted two different approaches for the saturation of the alkene. Upon treatment of
enone 192 with a catalytic amount of Pd/C in a hydrogen atmosphere resulted in a 4:1
mixture at C9. Unfortunately, the majority of the hydrogenated product consisted of the
proton placement at the opposite face of the natural product. In order to surmount this
issue, we utilized the diastereoselective hydrogenation method employed by Corey et.al.
to get the appropriate stereocenter at C-9.31 A high pressure (600psi) hydrogenation
facilitated by the chiral rhodium catalyst was used to give the desired isomer 193 in a 2:1
ratio. Based on NMR experimentation the bridgehead proton shift matched the spectral
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data of our previous synthesis of platensimycin indicating the correct isomer was the
major product (Scheme 2.10).

O

O

O

O

8

1. HF/Pyridine
0oC

O
CH3

187

OTBS

2. TsCl, Et3N, DMAP
CH2Cl2
rt

13

8

t-BuOK/ t-BuOH

O

CH3

O

O

C6H6, rt

3 steps, 60%
CH3

13

189

O

Cu(OAc)2, PdCl2,
O2 atm., rt

190

OTs

191

CH3

O
O
4

[Rh(cod)2]BF4
(-)-DIOP
H2 (600psi)

O

H

C

13
8

O
O

4

t-BuOK/ t-BuOH
C6H6, rt

58%

9

C

CH3

193

13

CH3

8

O
O

192

CH3

H2, Pd/C
Et3N, EtOAc
95% yield

4

H

C

13
8

O

194

CH3

Scheme 2.10 Progress towards cyclopentanone analogue

By using a previously published coupling procedure, final conversion to the
cyclopentanone analogue can be easily derived. The saturated ketone 193 when treated
with a bulky base such as LDA or LHMDS leads to enolate formation; this will block the
top face of the ring and allow for methylation from the less hindered side which generates
195. Michael addition using t-butylacrylate generates ester 196. Trifluoroacetic acid
promotes cleavage of the t-butyl group providing the acid 197, that can be coupled to the
aniline group to install the benzoic acid moiety found in the parent natural product.32
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Scheme 2.11 Proposed Route for Completion of 5-membered ring analogue

Synthesis of Acyclic Analogue Scaffolds
As outlined in Scheme 2.7 above, platensimycin contains the two distinct
domains, a polar head group (substituted benzoic acid moiety) and a lipophilic cage, that
are connected by an amide linker. We probed the lipophilic group to determine the
variance in biological activity by adjusting the structure to a more simplified version. We
have developed two series of acyclic analogs that we wish to synthesize and then test the
inhibition activity. First we synthesized an acyclic ring system in which the oxygen of
the ketone is displaced by an extended amine chain through reductive amination.33 The
simplified caged mimic 199 was attained from the alkylation of the activated keto
tosylate 188 in the presence of base. Following closure of the seco C-ring, reductive
amination occurs in the company of sodium triacetoxyborohydride to give the nitrogen
containing intermediate leading to analog 200 (Scheme 2.12).

Titanium isopropyl

tetraoxide provided a white precipitate upon addition to our homogenous mixture of the
primary amine and ketone. Imine formation appeared after about 3h of vigorous stirring.
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Removal of the methanol left a crude white solid residue which was redissolved in
dichloromethane, cooled to 0°C, and protonated with the hydride reducing agent to
furnish amine 200. The latter step of this stepwise or indirect reductive amination occurs
rather quickly resulting in a pair of inseparable diastereomers. It has been reported that
using sodium triacetoxyborohydride is less toxic and a milder reagent in comparison to
sodium cyanoborohydride. The three acetoxy groups stabilize the boron-hydrogen bond
which can be attributed to the mild reducing properties.34 As we analyze the binding
properties of the cage domain, a key hydrogen bond interaction occurs between the
carbonyl oxygen and A309 of FabF. The amino ester 200 was hydrolyzed under acid
catalysis

with

acetic

anhydride,

pyridine,

and

a

catalytic

amount

of

4-

dimethylaminopyridine (DMAP) leading to the corresponding acetamide 201.
Additionally, this acyl group will serve as an adequate protecting group of the secondary
amine to prevent zwitterionic reactions. Because the C-N peptide bond is stronger than
the labile hydrogen of the amine, it makes the compound extremely stable to mild acids.
Cleavage of the t-butyl ester protecting group in the presence of trifluoroacetic acid will
lead to the exposure of an easily accessible hydroxyl group of acid 202. Following the
aforementioned aniline coupling procedures utilized by Corey and co-workers will lead
to the completion of this acyclic bis-amine compound.
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Scheme 2.12 Progress towards synthesis of series I acyclic analogs
The aniline was generated by experimental procedures published by Giannis and
co-workers using a sequence of steps to form the amino acid (Scheme 2.13). This
aromatic ester was constructed starting with the commercially available methy-2,4dihydroxy benzoate 203. The methoxymethyl (MOM) protected benzoic ester 206 was
assembled in three sequential steps. Initial nitration of the phenol 203 was accomplished
with concentrated nitric acid, after which palladium-catalyzed hydrogenation leading to
the reduction of 204, and final etherification using chloromethyl methyl ether. Coupling
of the aniline to carboxylic acid 202 using HATU and triethyl amine followed by
elimination of all the protecting groups completed our synthesis towards acyclic analog I.
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Scheme 2.13 Aniline synthesis from Giannis’ Ester and final coupling
Conversion of intermediate 199 to acyclic analog series II can be constructed using
Wittig olefination to extend the carbon chain through the α,β-unsaturated ketone moiety.
In order to mimic the binding activity of the natural product within the FabF enzyme, we
examined a set of commercially available Wittig reagents which had a four carbon chain
extension containing the carboxylate ester attachment.

Many of them possessed an

additional ketone β to the ester group which is not observed in platensimycin. Therefore
we sought to create a methyl ester which has a single carbonyl encompassed in the amide
linker. Generation of this ylide could be easily assembled in situ via a one pot synthesis
using ordinary Wittig reaction protocols. Utilizing these procedures, methyl 4chlorobutyrate can be mixed with triphenylphosphine in the preparation of phosphonium
salt. Final conversion requires the addition of a strong base such as nBuLi to get the
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desired phosphorus ylide. Tricyclic ketone 199 can be coupled to the ylide furnishing the
olefinated intermediate. The double bond in intermediate 207 will be hydrogenated using
the Wilkinson’s catalyst followed by subsequent reduction of the ester to carboxylic acid
intermediate 208 using a strong base such as lithium hydroxide. Acid 208 will undergo
aniline coupling according to the procedures used by Corey and co-workers to obtain
acyclic analogue II (Scheme 2.14).

Scheme 2.14 Proposed synthesis of series II acyclic analogs
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Conclusions
We have demonstrated the usefulness of furan as a dependable synthon leading to
the most complex molecular scaffolds of natural products.

The highly oxygenated

oxaspirocyclic core of phelligridins G and E presents an interesting synthetic challenge,
while the potential anticancer and antioxidant properties of the molecules make them
compelling targets for study. Moreover, we have investigated two potential furan-based
routes to the oxaspiro core of those compounds.

Initial attempts to affect an

electrochemical oxidative cyclization were complicated by facile over-oxidation of the
products. An alternative route involving a challenging Diels-Alder cycloaddition with a
highly substituted 2-styrylfuran, followed by a tandem ring-opening/ring-closing
(domino) metathesis reaction proved successful. It was also possible to extend this
strategy to the higher homolog by using a formal [4+3] cycloaddition reaction with
tetrachlorocyclopropene. Current efforts towards the synthesis of phelligridin G based on
this strategy are ongoing.
For the antibiotic platensimycin we have developed novel analogs centered on
modifying the tetracyclic cage domain by applying a furan-based route with
tetrabromocyclopropene. We have replaced the six-membered cyclohexenone with a
five-membered cyclopentanone C-ring using our previously reported intramolecular
alkylation strategy to form our caged mimic. Additionally, we have achieved our second
goal by simplifying the cage region of the molecule by complete removal of the C-ring.
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These acyclic derivatives were constructed through displacement of the oxygen of the
carbonyl using amination and olefination methodologies. The complete syntheses of
these uniquely designed compounds are being investigated using the intermediates
synthesized on the preformed oxabicyclic core. Once the reaction sequence is complete
biological evaluations will proceed and be used for comparison to the parent
platensimycin.
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CHAPTER 3
EXPERIMENTAL PROCEDURES
General
All reactions were carried out under an inert argon atmosphere with dry solvents under
anhydrous conditions unless otherwise noted. Commercial grade reagents and solvents
were used without further purification except as indicated below. Hexanes,
tetrahydrofuran (THF), diethyl ether (Et2O), and dichloromethane (CH2Cl2) were used
directly from a Baker cycle-tainer system. Reagents were purchased at the highest
commercial quality and used without further purification, unless otherwise noted. Yields
refer to chromatographically and spectroscopically (1H-NMR) homogenous materials,
unless otherwise stated. Reactions were monitored by thin layer chromatography (TLC)
carried out on Whatman silica gel 60 Å precoated plates using UV light as the visualizing
agent and an acidic mixture of DNP or basic aqueous potassium permanganate (KMnO4)
and heat as developing agents. Flash chromatography was performed using Baker silica
gel (60 Å particle size). NMR spectra were recorded on Bruker-500 and 400 instruments
and calibrated using residual undeuterated solvent as an internal reference (CHCl3 at δ
7.26 ppm 1H NMR, δ77.1 ppm

13

C NMR). The following abbreviations were used to

explain the multiplicities: s = singlet, d = doublet, t= triplet, q = quartet, m = multiplet, b
= broad. IR Spectra were recorded on Shimadzu FT-IR 8400 spectrometer. Melting
points (m.p.) were uncorrected and measured with a Mel-Temp digital melting point
apparatus. High resolution mass spectra (HRMS) were obtained from the University of
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Connecticut Mass Spectral Facility by using Direct Analysis in Real Time using a Mass
Spectrometer: AccuTOF (JEOL).

2-Furan-2-yl-4,5-dimethoxybenzaldehyde (160)
Commercially available 3, 4-dimethoxy, bromobenzaldehyde 159 (0.5g, 2.04mmol) was
added to an argon purged 25 ml flask. Anhydrous THF (10mL) was added followed by
2-furan boronic acid 158 (2 equiv.), and PdCl2(PPh3)2 (0.1 mol equiv.). Once all the
reagents were in solution, 2M aqueous solution of Cs2CO3 (3 mol equiv.) was added to
the flask, immediately added to the preheated oil bath. It was refluxed with vigorous
stirring for 2-24 hrs. Once the reaction was deemed complete, it was cooled to room
temperature, quenched with H2O, and diluted with Et2O. The aqueous layer was extracted
with Et2O (3 x 5mL) and the combined organic layers were washed with brine, dried over
Na2SO4, and concentrated to give a crude yellow solid. The crude product was purified
by column chromatography on silica gel (6:1 hexane/ethyl acetate) to yield (95%) 160 as
a solid. Rf = 0.38; m.p.= 102ºC; IR (KBr, cm-1): υ: 730, 909, 1280, 2255, 3012 1H NMR
(400MHz CDCl3): δ= 3.96-4.04 (m, 6H), 6.58 (s, 2H), 7.13 (s, 1H), 7.54 (s, 1H), 7.62 (s,
1H), 10.27 (s, 1H).

13

C NMR (126MHz, CDCl3) δ=190.58, 154.46, 153.48, 150.43,

149.04, 143.47, 128.85, 126.67, 115.40, 111.76, 110.38, 108.83, 77.44, 77.12, 76.80,
65.76, 56.00; HRMS (DART) calcd for C13H13O4 [M+H]+: 233.0814; found 233.0823.
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(tert-Butyl-dimethyl-silanyloxy)-2-furan-2’-yl ‘4,5’-dimethoxy-phenyl)-acetonitrile (161)
To a flame dried flask was added t-butyl dimethylsilylcyanide (0.141g, 1.0mmol),
potassium cyanide (0.003g, 0.05mmol), and 18-crown-6 (0.053g, 0.4mmol) under an
argon atmosphere. A solution of aldehyde 160 (0.116g, 0.500mmol) in dry methylene
chloride (5mL) was added over 30 minutes to the homogenous mixture drop-wise. The
reaction was stirred vigorously for 24 hrs and monitored by TLC. Upon completion the
solvent is removed in vacuo and the crude oily residue was purified by flash
chromatography using 15% EtOAc in hexanes solution. The silyl cyanide 161 was
obtained as a pure yellow oil (0.177g, 95% yield).Rf= 0.67; IR(KBr, cm -1) υ: 654, 735,
908, 2254, 2962, 3012 1H NMR (500MHz CDCl3): δ= 0.02-0.12 (d, J=50Hz, 6H), 0.89
(s, 9H), 3.93-3.95 (d, J=10Hz, 6H), 5.89 (s, 1H), 6.53 (s, 2H), 7.02 (s, 1H), 7.30 (s,1H),
7.55 (s, 1H).

13

C NMR (126MHz, CDCl3) δ=151.8, 149.5, 147.2, 126.6, 121.8, 119.7,

111.8, 110.9, 110.1, 108.9, 61.2, 56.2, 25.7, 18.3, -5.1; HRMS (DART) calcd for C20H28
NO4Si [M+H]+: 374.1788; found 374.1776.
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(tert-Butyl-dimethyl-silanyloxy)-2-furan-2’-yl‘4,5’-dimethoxy-phenyl)-acetaldehyde (162)
The silyl cyanide 161 (0.455g, 1.22mmol) was dissolved in dry toluene (4mL) and cooled
to -78°C. DIBAL (0.868g, 6.1mmol) was added drop-wise to the flask and stir 2 hrs at
this temp. Once the imine is formed, the reaction was quenched with methanol (2.1mL)
and warmed up to 0°C. After 2 hrs, 1N H2SO4 (2mL) was added drop-wise to the mixture
while stirring for 1 hr at this temperature. Add diethyl ether to dilute the reaction and the
aqueous layer was separated. Extract aqueous layer with ether (3x 3mL) and collect
ethereal layer. Wash with brine and dry over Na2SO4, and remove organics in vacuo. The
crude oil was purified by flash chromatography using a 10% EtOAc in hexanes solution
to obtain 162 as pure oil (0.200g, 44% yield). Rf= 0.49; IR(KBr, cm -1) υ: 732, 913,
1735, 2934, 2959, 3012 1H NMR (500MHz CDCl3): δ= -0.09-0.02 (d, J=-35Hz, 6H),
0.87 (s, 9H), 3.91-3.92 (d, J=5, 6H), 5.50 (s, 1H), 6.49-6.61 (dd, J= 10, 5, 2H), 7.07-7.09
(d, J=10, 2H), 7.51 (s,1H).

13

C NMR (126MHz, CDCl3) δ=198.9, 152.3, 149.3, 148.9,

142.4, 127.2, 122.8, 111.5, 111.2, 110.5, 108.9, 76.2, 56.0, 25.7, 25.7, 18.3, -4.9; HRMS
(DART) calcd for C20H29O5Si [M+H]+: 377.1784; found 377.1760.
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Tert-Butyl-[1-(2-furan-2’yl-4’,5’-dimethoxy-phenyl)-3-methoxy-allyloxy]dimethyl-silane
(163)
To a stirred solution of dry THF (3mL) was added methoxymethyl triphenylphosphonium
bromide (0.36g, 0.105mmol) under argon. The homogenous mixture was cooled to 0ºC
followed by addition of NaOtBu base (2eq.) in one portion. The red-orange suspension
was stirred about 30 mins as the color persisted under the above temp. A 0.20mM
solution of 2-furyl benzaldehyde 162 (0.802g, 3.45mmol) in THF was slowly added, and
the reaction was monitored by TLC at 0ºC. The reaction was quenched with H2O (2mL)
and diluted with ether (4mL). The aqueous layer was extracted with Et2O, and the
combined extracts were washed with H2O and Brine then dried over Na2SO4. Removal of
all organics was done in vacuo to yield crude oily residue as E/Z isomers of 163 (0.020g,
64%). Rf =0.33; IR (KBr, cm-1): υ: 812, 1278, 1687, 2857, 3233;

1

H NMR (500MHz

CDCl3): δ= -0.11-0.05 (d, J=-30Hz, 6H), 0.86 (s, 9H), 3.48 (s,1H), 3.91-3.92 (d, J=5Hz,
6H), 4.90-4.94 (m, J = 20Hz, 1H), 5.59-5.60 (d, J =5Hz, 1H), 6.29-6.32 (d, J=15Hz, 1H),
6.37-6.48 (m, J= 55Hz, 2H), 6.97 (s,1H), 7.22(s,1H), 7.49 (s,1H).

13

C NMR (126MHz,

CDCl3) δ= 153.0, 149.2, 148.8, 147.7, 141.8, 135.7, 120.7, 111.4, 110.9, 109.9, 108.1,
107.3, 69.1, 56.1, 56.0, 25.9, 18.4, -4.7, -4.7; HRMS (DART) calcd for C22H33O5Si
[M+H]+: 405.2097; nodetection.
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(tert-Butyl-dimethyl-silanyloxy)-2[5-tert-butyl-dimethyl-silanyloxymethyl-furan-2-yl]4,5dimethoxy-phenyl-acetaldehyde (164a)
Compound 164b was synthesized using the previous procedure above to assemble enol
ether 163. Bromo aldehyde 159 dissolved in dry methylene chloride was added dropwise
to a stirring mixture of TBSCN, 18-crown-6, and KCN. Coupling occurred with standard
Suzuki conditions as mentioned above, but the 2-furan boronic acid 158 was replaced
with the disubstituted 5-formyl-2-furanylboronic acid. After coupling the furaldehyde,
the carbonyl was reduced to the primary alcohol after that protection using TBSCl to
generate the aldehyde 164a (0.025g, 50% yield). Rf =0.50 (25% EtOAc in hexanes); IR
(KBr, cm-1): υ: 838, 1079, 1234, 1414,1509, 2253,2956; 1H NMR (500MHz CDCl3): δ=
-0.09-0.01 (d, J=-40Hz, 6H), 0.10 (s, 6H), 0.87 (s, 9H), 0.91 (s, 9H), 3.90-3.92 (d,
J=10Hz, 6H), 4.69 (s, 2H), 5.52-5.53 (d, J =5Hz, 1H), 6.33-6.56 (d, J=5Hz, 2H), 7.09
(s,2H), 9.61 (s,1H).

13

C NMR (126MHz, CDCl3) δ= 191.1, 167.1, 163.5, 156..3, 152..4,

148.3, 147.9, 129.2, 122.8, 112.6, 110.7, 109.6, 104.3, 98.8, 69.1, 56.3, 56.2, 29.9, 26.1,
25.8, 18.8, 18.2, -3.4, -4.1, -4.9; HRMS (DART) calcd for C27H44O6Si2 [M+H]+:
520.2676; 520.2662.
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2-2-[1-tert-Butyl-dimethyl-silanyloxy)-3-methoxy-allyl]-4,5-dimethoxy-phenyl)-5-tertbutyl-dimethyl-silanyloxymethyl-furan (164b)
Employing Wittig olefination we were able to get the methoxy vinyl intermediate. To a
stirred solution of dry THF (3mL) was added methoxymethyl triphenylphosphonium
bromide (0.36g, 0.105mmol) under argon. The homogenous mixture was cooled to 0ºC
followed by addition of NaOtBu base (2eq.) in one portion. The red-orange suspension
was stirred about 30 mins as the color persisted under the above temp. A 0.20mM
solution of 2-furyl benzaldehyde 164a (0.802g, 3.45mmol) in THF was slowly added,
and the reaction was monitored by TLC at 0ºC. The reaction was quenched with H2O
(2mL) and diluted with ether (4mL). The aqueous layer was extracted with Et2O, and the
combined extracts were washed with H2O and Brine then dried over Na2SO4. Removal of
all organics was done in vacuo to yield an oily residue as E/Z isomers of 164b (0.020g,
64%). This crude product was readily available to undergo anodic oxidation.

4-(2-Furan-2-yl-4,5-dimethoxy-phenyl)-but-3-en-2-one (165a)
Dissolve 2-phenylfuran 158 in CH2Cl2 (6mL) followed by 1-triphenylphosphoranylidene2-propanone (0.557g, 1.75mmol). The solution was placed into a preheated oil bath
(41°C) and stirred 48h under reflux monitoring progress by TLC (30%EtOAc in
hexanes).

Upon completion the solvent was removed in vacuo to get a crude product
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which was purified by flash chromatography starting with a flushing the column with
pure hexanes to remove any triphenylphosphine present. The polarity was increased to
12% EtOAc in hexanes solution while gradually increasing to 15% EtOAc in hexanes to
get methyl ketone 165a as pure oil (0.115g, 68% yield). [Note: there was some mixed
product containing desired ketone and unwanted starting aldehyde; therefore needed to
run a second column for optimum purity]. Rf =0.10(25% EtOAc in hexanes); IR (KBr,
cm-1): υ: 728, 913, 1136, 1256, 1659, 2243,2938;

1

H NMR (500MHz CDCl3): δ= 2.37

(s,3H), 3.95-3.97 (d, J=10Hz, 6H), 6.39-6.40 (d, J=5Hz, 1H), 6.54-6.58 (d, J=20, 1H),
6.58-6.61 (d, J=15 Hz, 1H), 7.10 (s,1H), 7.14 (s,1H), 7.56 (m,1H), 7.90-7.94 (d, J= 20Hz,
1H).

13

C NMR (126MHz, CDCl3) δ= 198.6, 151.9, 150.9, 149.1, 142.8, 142.4, 141.0,

127.4, 125.5, 124.8, 111.9, 110.5, 110.4, 109.2, 56.1, 56.1, 27.2; HRMS (DART) calcd
for C16H17O4 [M+H]+: 273.1126; found 273.1115.
[3-(2-furan-2-yl-4,5-dimethoxy-phenyl)-1-methyl-propenyloxy]-trimethyl-silane (165b)
Silyl ether 165b was obtained using the Wilkinson’s catalyst followed by trapping the
enolate with Et3SiH. The methyl ketone 165a (0.057g, 0.209mmol), ClRh(PPh3)3 (2mg,
0.002mmol), Et3SiH (0.027g, 0.230mmol) were all dissolved in benzene (0.21mL) in a
pressure vial under argon. The vial was capped then placed in oil bath at 50°C and
monitored until deemed complete (~4h). The benzene was removed to get crude residue
which could be used for electrochemical oxidation without any further purification [74%
yield of E/Z isomers (1:0.5)]. Rf =0.30(25% EtOAc in hexanes); IR (KBr, cm-1): υ: 912,
1278, 1687, 2242, 2957; 1H NMR (500MHz CDCl3): δ= 0.63-0.64 (d, J=-5Hz, 6H), 1.00
(s, 9H), 1.73 (s,3H), 3.46-3.50 (d, J=20Hz, 6H), 3.75-3.77 (d, J=10Hz, 2H), 4.69 (m,
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1H), 6.30 (s, 1H), 6.57 (s, 1H), 6.91 (s, 1H), 7.16 (s,1H), 7.32 (s,1H).

13

C NMR

(126MHz, CDCl3) δ= 153.8, 149.6, 148.1, 147.1, 141.0, 131.9, 128.2, 122.8, 113.9,
111.9, 111.3, 107.7, 107.4, 55.3, 55.2, 30.0, 29.8, 22.4, 6.7, 6.6, 5.9, 5.7; HRMS (DART)
calcd for C22H32O4Si[M+H]+: 388.5726:[crude sample so no data obtained]

Tert-Butyl-[3-ethoxy-1-(2-furan-2-yl-4,5-dimethoxy-phenyl)-prop-2-ynloxy]-dimethylsilane (166b)
Add ethyl ethynyl ether (0.06g, 0.861mmol) into THF (4mL) at -10°C under an argon
atmosphere followed by 2.45M n-BuLi (0.37mL, 0.905mmol) solution and stir at 0°C.
After 30 mins the temperature was cooled to -78°C and a solution of aldehyde 158
(0.100g, 0.43mmol) mixed with HMPA (0.45mL, 2.54mmol) was added dropwise to the
flask which was warmed up to 0°C. The reaction was stirred vigorously and monitored by
TLC in 3:1 Hex:EtOAc solution until deemed complete. Upon completion the reaction
was quenched with sat.aq.NH4Cl (3mL). The mixture was placed in separatory funnel to
separate the organics followed by extraction of the aqueous layer with EtOAc and the
combined extracts were washed with H2O and Brine then dried over Na2SO4. The
solvent is removed in vacuo and the crude oily residue was purified by flash
chromatography using 15% EtOAc in hexanes to remove HMPA and any residual
starting material; next the eluent was increased to 25% EtOAc in hexanes solution to get
the alkenyl alcohol 166a (0.085g, 65%). [Rf= 0.26 (25% EtOAc in hexanes)]
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Alcohol 166a (0.085g, 0.281mmol) was placed into round bottom flask dissolving in
CH2Cl2 (5mL) followed by imidazole (0.077g, 1.12mmol), and DMAP (10 mol%). Cool
the homogenous mixture to 0°C and add TBSCl (0.085g, 0.562mmol) dropwise while
stirring vigorously. Slowly warm up to ambient temperatures and continue stirring until
silylation is complete monitored by TLC (6:1 Hex:EtOAc). Filter solution through Celite
and wash with CH2Cl2. Remove solvent in vacuo and the crude oily residue was purified
by flash chromatography using 15% EtOAc in hexanes solution to get silyl ether 166b as
a pure oil (0.067g, 74% yield).Rf= 0.41; IR(KBr, cm -1) υ: 746, 865, 1244, 1515, 2262,
2900 1H NMR (500MHz CDCl3): δ= 0.02-0.05 (d, J=15Hz, 6H), 0.87 (s, 9H), 1.30-1.33
(t, J=10, 5Hz, 3H), 3.92-3.94 (d, J=10Hz, 6H), 4.02-4.06 (m, 2H), 5.78 (s, 1H), 6.49-6.65
(dd, J=5, 5Hz, 2H), 7.09 (s, 1H), 7.36 (s,1H), 7.49 (s, 1H).

13

C NMR (126MHz, CDCl3)

δ=152.2, 148.9, 148.1, 141.8, 133.8, 120.6, 111.6, 110.2, 109.9, 108.7, 94.4, 74.6, 61.8,
56.1, 56.0, 40.4, 26.0, 18.5, 14.6, -4.3, -4.6; HRMS (DART) calcd for C23H33O5Si
[M+H]+: 417.2097; found 417.2086.

Tert-Butyl-[2-{1,3}dithian-2-ylidene-1-(2-furan-2-yl-4,5-dimethoxy-phenyl)-ethoxy]dimethyl-silane (167)
Peterson olefination conditions were used. Place 1,3-dithiane (0.126g, 0.655mmol) into
dry THF (1.32mL) cool to -78°C, followed by dropwise addition of 2.0M nBuLi in
hexanes solution (0.39mL, 0.779mmol). Once all the base was added warm up to 0°C and
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stir for 5h. After lithiation has successfully occurred, cool the reaction back to -78°C and
add aldehyde 162 (0.312g, 0.829mmol). Allow to reach room temperature with
continuous stirring until starting material consumed. The reaction was quenched with
H2O, and then poured into separatory funnel for extraction with CH2Cl2. Brine was
added to remove emulsion from the cloudy mixture. The combined ethereal layers were
washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude residue
could be purified by flash chromatography using 10% EtOAc in hexanes solution to give
diastereomers (1:0.5 trans:cis) of dithiane 167. Rf =0.33; IR (KBr, cm-1): υ: 812, 1278,
1687, 2857, 3233; 1H NMR (500MHz CDCl3): δ= -0.04-0.07 (d, J=15Hz, 6H), 0.88 (s,
9H), 2.14-2.16 (m,1H), 2.82-2.92 (m, 1H), 3.91-3.94 (d, J=15Hz, 6H), 6.04 (s, 1H), 6.456.50 (m, J= 25Hz, 2H), 6.95 (s,1H), 7.23(s,1H), 7.28-7.29 (d, J=5Hz,1H) 7.53-7.55 (d,
J=15Hz, 1H).

13

C NMR (126MHz, CDCl3) δ= 152.7, 149.2, 147.8, 141.9, 135.1, 129.1,

129.0, 128.2, 121.2, 117.8, 111.8, 110.0, 108.3, 107.3, 99.4, 67.8, 55.9, 55.8, 29.8, 29.5,
25.9, 18.2, -4.4, -4.7; HRMS (DART) calcd for C24H34O4S2Si [M+H]+: 479.1746;
[nodetection: crude sample]

2-(4,4-Dimethoxy-2-vinylphenyl)furan (171)
To a stirred solution of dry THF (36mL) was added methyl triphenylphosphonium
bromide (1.52g, 4.32mmol) under argon. The homogenous mixture was cooled to 0ºC
followed by dropwise addition of a 2.5M solution n-BuLi in hexanes (1.25eq.). The red82

orange suspension was stirred about 30 mins as the color persisted under the above temp.
A 0.53mM solution of 2-furyl benzaldehyde 160 (0.802g, 3.45mmol) in THF was slowly
added, and the reaction was complete at 0ºC after 10-15mins. The reaction was quenched
with sat. aq.NH4Cl (10mL) and diluted with EtOAc (20mL). The aqueous layer was
extracted with EtOAc, and the combined extracts were washed with H2O and Brine then
dried over Na2SO4. Removal of all organics was done in vacuo to yield crude solid
material, which was purified by silica gel column chromatography (hexane:EtOAc, 10:1)
to yield olefin 171 as yellow oil (0.568g, 72%). Rf =0.43; IR (KBr, cm-1): υ: 730, 909,
1266, 2254, 3007 1H NMR (500MHz CDCl3): δ= 3.93-3.95 (d, 6H, J=3.3Hz), 5.24-5.26
(dd, J = 5, 5Hz, 1H), 5.59-5.62 (d, J =15Hz, 1H), 6.42-6.49 (d, J=35Hz, 2H), 7.99-7.05
(m, J= 30Hz, 1H), 7.03(s,1H), 7.12(s,1H), 7.48 (s,1H).

13

C NMR (126MHz, CDCl3) δ=

152.64, 148.91, 141.91, 135.98, 128.73, 122.63, 114.14, 111.56, 110.39, 109.39, 56.16,
56.11; HRMS (DART) calcd for C14H15O3 [M+H]+: 231.1021; found 231.1000.

1-(4’,5’-Dimethoxy-2’vinylphenyl)-7-oxabicyclo[2.2.1]hepta-2,5diene-2,3-dicarboxylic
acid dimethylester (174)
Dimethoxy benzylfuran 171 (343mg,1.49mmol) was added to a flame dried vial in
benzene(0.37mL) to make a 3mM solution followed by addition of DMAD
(233mg,1.64mmol) at room temperature. The reaction stirred vigorously until everything
83

was in solution then added to preheated oil bath at 40ºC. The reaction was monitored by
TLC using a 30% EtOAc in hexanes solution. Upon completion the organics were
removed in vacuo to afford a crude oil, which was purified by silica gel chromatography
(SiO2,7g; 25%EtOAc in hexanes) to yield cycloadduct 174 as an oil.(0.264g, 55%):Rf
=0.21; IR (KBr, cm-1): υ: 731, 908, 1268, 2345, 3016; 1H NMR (500MHz CDCl3): δ=
3.57 (s, 3H), 3.74 (s, 3H), 3.84-3.86 (d, J=10Hz, 6H), 5.14-5.16 (d, J = 10Hz, 1H), 5.505.54 (d, J =20Hz, 1H), 5.75 (s, 1H), 6.92-7.02 (dd, J=15Hz, 15Hz, 1H ), 7.01-7.03 (d,
J=10Hz, 2H), 7.27-7.28(dd, J=5Hz, 1H), 7.47-7.48 (d, J= 5Hz, 1H).

13

C NMR

(126MHz, CDCl3) δ= 164.9, 162.7, 158.8, 149.4, 149.2, 148.6, 145.2, 144.7, 134.7,
130.0, 123.6, 114.7, 110.9, 109.4, 97.9, 83.5, 55.9, 52.4; HRMS (DART) calcd for
C20H21O7 [M+H]+: 373.1287; found 373.1280.

4’5’Dimethoxyspiro[5-oxa-furyl-2,3 di(methoxycarbonyl)-4-vinyl-]-1,1’[1H]indene (175)
To a solution of oxabicyclic ether 174 (177mg, 0.475mmol) in dry dichloromethane
(47.5mL) 0.01mM was added a solution of Grubbs 2nd generation catalyst (G-II) 78
(40mg, 0.0475mmol) in 1ml CH2Cl2 at room temperature. The reaction was stirred
vigorously at room temperature then placed into preheated oil bath at 35ºC. The reaction
was monitored by 1Hnmr until deemed complete. After 24hrs of heating, the reaction was
removed from heat and concentrated to crude brown oil. Purification of the residue by
flash chromatography using 25% EtOAc in hexanes afforded pure spirocyclic compound
84

175 (.048g, 50%).Rf = 0.21(25% EtOAc in hexanes); IR (KBr, cm-1): υ: 732, 907, 1255,
2253, 2955; 1H NMR (500MHz CDCl3): δ= 3.56 (s, 3H), 3.81 (s, 3H), 3.87-3.89(d,
J=10Hz, 6H), 5.28-5.30 (d, J =20Hz, 1H), 5.48-5.51 (d, J=15, 1H), 5.76-5.78 (s,1H)
5.99-6.04 (m, 1H), 6.16-6.17 (d, J=5.5Hz, 1H), 6.61-6.62 (d, J=5.5Hz, 1H), 6.76(s,1H),
6.89 (s, 1H).

13

C NMR (126MHz, CDCl3) δ= 163.1, 162.3, 150.3, 148.4, 142.9, 136.7,

136.6, 135.7, 133.7, 128.8, 127.0, 118.1, 107.8, 105.8, 99.38 86.4, 56.5, 56.6, 52.6;
HRMS (DART) calcd for C20H21O7 [M+H]+: 373.1287; found 373.1283

1-(2’-Formyl-4’,5’dimethoxy-phenyl)-7-oxa-bicyclo[2.2.1]hepta-2,5-diene2,3dicarboxylic acid dimethyl ester (173)
Dimethoxy-furyl benzaldehyde 160 (343mg,1.49mmol) was added to a flame dried vial
in benzene(0.37mL) to make a 3mM solution followed by addition of DMAD
(233mg,1.64mmol) at room temperature. The reaction stirred vigorously until everything
was in solution then added to preheated oil bath at 50ºC. The reaction was monitored by
TLC using a 30% EtOAc in hexanes solution. Upon completion the organics were
removed in vacuo to afford a crude oil, which was purified by silica gel chromatography
(SiO2,7g; 25%EtOAc in hexanes) to yield cycloadduct 173 as an oil. Diastereomers were
obtained which could be separated via column chromatography.(0.202g, 50% of desired
product):Rf =0.085; Rf =0.17; m.p.= 175ºC; IR (KBr, cm-1): υ: 730, 912, 1291, 1684,
85

3024; 1H NMR (500MHz CDCl3): δ= 3.63 (s, 3H), 3.81 (s, 3H), 3.97-3.98 (d, J=5Hz,
6H), 5.76 (s, 1H), 7.21(s, 1H ), 7.25 (s, 2H), 7.30-7.33(dd, J=5, 5Hz, 1H), 7.45 (s,1H),
10.03(s, 1H).

13

C NMR (126MHz, CDCl3) δ= 190.9, 164.1, 162.7, 156.8, 153.5, 148.9,

148.3, 144.9, 143.3, 129.9, 126.9, 114.6, 110.3, 96.6, 82.6, 56.2, 56.1, 52.3, 52.2; HRMS
(DART) calcd for C19H18O8:[M+H]+: 375.1080; found 375.1069.

4’,5’-Dimethoxy-2-(2,3,4,4-tetrachloro-8-oxa-bicyclo[3.2.1]octa-2,6-dien-1-ylbenzaldehyde (176)
Dimethoxy furyl- benzaldehyde 160 (0.237mmol) was dissolved in benzene to make a
2.97M

solution

at

room

temperature

followed

by

addition

of

tetrachlorocyclopropene(1eq.). The homogeneous mixture was stirred vigorously and
heated to 55ºC and stirred for 3-4 days. The reaction was monitored by TLC using a 25%
EtOAc in hexanes solution. Upon completion the organics were removed in vacuo to
afford a crude solid, which was purified by flash chromatography (SiO2, 9g; 25%EtOAc
in hexanes) to yield yellow solid 176. (0.42g, 68%): Rf =0.67; m.p.=175ºC; IR (KBr, cm1

): υ: 733, 907, 1277, 1516, 2938; 1H NMR (500MHz CDCl3): δ= 3.98-4.07 (d, J= 43Hz,

6H), 5.46 (s, 1H), 7.00 (s, 1H), 7.30 (s,1H), 7.59 (s,1H), 10.23 (s, 1H).

13

C NMR

(126MHz, CDCl3) δ= 190.1, 153.0, 150.2, 144.7, 138.7, 129.4, 127.9, 122.5, 112.6,
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110.3, 94.2, 82.6, 75.2, 64.1, 63.3, 56.3, 56.2; HRMS (DART) calcd for C16H13Cl4O4
[M+H]+: 410.9540; found 410.9540.

2,3,4,4,Tetrachloro-1-(4’,5’dimethoxy-2’-vinyl-phenyl-8oxa-bicyclo[3.2.1]octa-2,6-diene
(177)
Cycloadduct 176 (0.237mmol) was olefinated as mentioned above to give crude
compound 177 which was purified using flash chromatography on silica gel
(hexane:EtOAc, 20:1) to yield a yellow solid (0.57g, 45%).Rf =0.71; IR (KBr, cm-1): υ:
731, 908, 2252, 2941, 3014; 1H NMR (500MHz CDCl3): δ= 3.95-3.99(d, J=16Hz, 6H),
5.18-5.21 (d, J = 12Hz, 1H), 5.39(s, 1H), 5.54-5.57 (d, J = 12Hz, 1H), 6.88-7.00 (dd,
J=4Hz, dd, J=8Hz, 1H ), 6.93(s, 1H), 6.96 (s, 1H), 7.09 (s,1H), 7.19 (s,1H).

13

C NMR

(126MHz, CDCl3) δ= 150.3, 148.4, 145.2, 137.3, 135.1, 132.7, 120.8, 115.0, 113.5,
110.0, 95.6, 82.4, 75.5, 64.7, 63.6, 56.2,56.1; HRMS (DART) calcd for C17H15Cl4O3
[M+H]+: 408.9747; found 408.9767.
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4’5’Dimethoxy spiro[6-oxa-pyrano-2,3,4,4 tetrachloro-5-vinyl]-1,1’[1H]indene (178)
Purification of the crude residue 178 by flash chromatography using 25% EtOAc in
hexanes afforded pure spiro-fused pyran. Yield: (0.048g, 48%).Rf = 0.30; IR (KBr, cm1

): υ: 733, 912, 2324, 2861, 2943; 1H NMR (500MHz CDCl3): δ= 3.90-3.91 (d, J=5Hz,

6H), 5.07-5.08 (d, J =5Hz, 1H), 5.45-5.47 (d, J=10, 1H), 5.52 (s, 1H) 6.12-6.13 (d,
J=5Hz, 1H), 6.22-6.28 (m, J=30Hz, 1H), 6.59-6.60 (d, J=5Hz, 1H), 6.81(s,1H), 7.68 (s,
1H).

13

C NMR (126MHz, CDCl3) δ= 150.9, 148.5, 144.9, 137.8, 137.3, 134.3, 132.6,

131.3, 124.9, 121.2, 111.8, 106.5, 84.0, 70.20, 59.53, 56.6, 56.4; HRMS (DART) calcd
for C17H15Cl4O3 [M+H]+: 408.9747; found 408.9772.
O
CH 3

178 CO Me
2

1. LAH, THF, 0oC
2. TBSCl, Imidazole,
DMAP, CH 2Cl2
0oC

O
CH 3

179

OTBS

Tert-Butyl-dimethyl-(2-methyl-furan-3-ylmethoxy)-silane (179)
A solution of lithium aluminum hydride (1.8g, 46.4mmol) was added to dry THF (40mL)
at 0°C, followed by slow addition of methyl 2-methyl-3-furancarboxylate 178 (5.0g,
35.7mmol). After 15 mins reduction of the methylester was complete, and the reaction is
quenched via dropwise addition of H2O (1.8mL), 15%NaOH (1.8mL), then H2O (5.4mL).
Continue stirring for 1h followed by dilution with Et2O (20mL). Filter the precipitate
thru funnel and collect the ethereal layers. Dry over MgSO4 (25-30mins) then evaporate
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most of the ether in vacuo to afford the primary alcohol without any further purification.
[Note: Compound sits on baseline of TLC plate in 8:1 Hex:EtOAc and is not UV active,
however illuminates after staining in KMnO4]
The crude alcohol (35.7mmol) was placed into round bottom flask dissolving in CH2Cl2
(70mL) followed by imidazole (3.64g, 53.5mmol), and DMAP (0.871g, 7.14mmol). Cool
the homogenous mixture to 0°C and add TBSCl (5.38g, 35.7mmol) dropwise while
stirring vigorously. Slowly warm up to ambient temperatures and continue stirring until
silylation is complete monitored by TLC (8:1 Hex:EtOAc). Filter solution through Celite
and wash with CH2Cl2. Remove solvent in vacuo and the crude oily residue was purified
by flash chromatography to furnish furan 179 as a pure clear oil (5.35g, 85% yield)
(SiO2, 240g, 10% EtOAc in hexanes): Rf = 0.68 (12% EtOAc in hexanes); IR (KBr, cm1

): υ: 939, 1258, 1629, 2736, 2966; 1H NMR (500MHz CDCl3): δ= 0.08 (s, 6H), 0.91 (s,

9H), 2.26 (d, J =15.9,Hz, 3H), 4.51 (s 2H), 6.31 (s, 1H), 7.27 (d, 1H)

13

C NMR

(126MHz, CDCl3) δ= 148.2, 140.3, 119.3, 111.2, 57.4, 26.2, 18.6, 11.9, -4.9; HRMS
(DART) calcd for C12H22O2Si [M+H]+: 225.1311; found 225.1296.

3,4-Dibromo-6-hydroxymethyl-5-methyl-8-oxa-bicyclo[3.2.1]octa-3,6-dien-2-one
To a flame dried pressure tube was added furan 179 (2.86g, 12.63mmol) and benzene
(4.2mL,

2.97M)

under

argon

atmosphere.
89

The

solution

was

treated

with

tetrabromocyclopropene (4.40g, 12.63mmol) at room temperature and the tube was
sealed. The tube was placed in an oil bath at room temperature then gradually heated to
90°C for about 2h. Upon completion the solution was cooled to room temperature and all
volatiles were removed in vacuo to give the crude tetrabromide as an inconsequential
mixture of regioisomers 180a and 180b (1.4:1, 1H NMR).
The crude mixture (12.63mmol) was dissolved in acetone-H2O (2:1, 64 mL) and treated
portionwise with AgNO3 (4.29g, 25.26 mmol) over a 30 min period. The reaction
mixture was allowed to stir at room temperature for 2h before being poured over solid
NaHCO3 (4.24g), H2O (100mL), brine (100 mL), dried over Na2SO4, and concentrated to
give the crude dibromoenone as a mixture of regioisomers (4:1, 1H NMR). The crude
material was purified by flash chromatography (SiO2, 150g, 25% EtOAc in hexanes) to
provide 1.90 g of mixed regioisomers (183+184) and 183 (3.2 g, 80% overall) as a pale
yellow oil: Rf = 0.24 (25% EtOAc in hexanes); IR (KBr, cm-1): υ: 1049, 1539, 1704,
3470; 1H NMR (500MHz CDCl3): δ= 1.78 (s, 3H), 1.81 (bs, 1H), 4.39 (ddd, J =15.9, 1.9,
1.1 Hz, 1H), 4.45 (dt, J=15.8, 1.7Hz, 1H), 5.12 (dt, J= 2.4, 1.2Hz, 1H), 6.27 (dd, J= 4.0,
2.0Hz, 1H) 13C NMR (126MHz, CDCl3) δ= 183.7, 156.4, 153.2, 123.9, 121.2, 91.3, 85.9,
58.6, 21.5; HRMS (ESI) calcd for C9H8Br2NaO3 [M+Na]+: 344.8738; found 344.8732.
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3,4-Dibromo-6-(tert-butyl-dimethyl-silanyloxymethyl)-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (185)
Alcohol 183 (2.73g, 8.43 mmol) was dissolved in CH2Cl2 (17mL), cooled to -78°C, and
treated with 2,6-lutidine (1.47mL, 12.65 mmol). To the cooled solution was added
TBSOTf (2.13mL, 9.27 mmol) and continued to stir for 1h. Upon completion, the
reaction was quenched by addition of H2O and the biphasic mixture was allowed to warm
up to room temperature. The layers were separated and the aqueous layer extracted with
CH2Cl2 (3 x 30mL). The combined ethereal layers were washed with brine (50mL), dried
over Na2SO4, and concentrated in vacuo. The crude material was purified by flash
chromatography (SiO2, 50 g, 10% EtOAC in hexanes) to afford 185 (3.53g, 96%) as a
yellow oil: Rf = 0.68 (15% EtOAc in hexanes); IR (KBr, cm-1): υ: 839, 1072, 1541, 1710,
2929, 2953; 1H NMR (500MHz CDCl3): δ= 0.07 (s,3H), 0.08 (s,3H), 0.90 (s,9H), 1.75 (s,
3H), 4.35 (ddd, J =15.8, 2.0, 1.0 Hz, 1H), 4.40 (dt, J=15.8, 1.8Hz, 1H), 5.10 (dt, J= 2.4,
1.3Hz, 1H), 6.19 (q, J= 1.9Hz, 1H) 13C NMR (126MHz, CDCl3) δ= 183.8, 156.7, 153.1,
123.4, 121.1, 91.2, 85.9,

59.1, 25.6, 21.6, 18.3, -5.4, -5.5; HRMS (ESI) calcd for

C15H23Br2O3 Si [M+H]+: 436.9783; found 436.9778.
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6-(tert-Butyl-dimethyl-silanyloxymethyl)-5-methyl-8-oxa-bicyclo[3.2.1]octan-2-one(186)
Dibromoenone 185 (1.01g, 2.30 mmol) was dissolved in EtOAc (4.6mL) and treated with
Et3N (2.24mL, 16.13 mmol). To the solution was added 10% Pd/C (1.0g) and the flask
was evacuated and backfilled with H2 (3 cycles). The reaction mixture was stirred under
an atmosphere of H2 (balloon) for 4h before being filtered through a pad of SiO2 eluting
with EtOAc (100mL). The solvent was removed under vacuum and the residue was
purified by flash chromatography (SiO2, 40g, 10% EtOAc in hexanes) to give ketone 186
(1.60g, 70%) as a clear oil; Rf = 0.61 (15% EtOAc in hexanes); IR (KBr, cm-1): υ: 838,
1078, 1095, 1732, 2930, 2955; 1H NMR (500MHz CDCl3): δ= 0.06 (s,3H), 0.89 (s,9H),
1.43 (s, 3H), 1.50-1.56 (m, 1H), 1.94-2.02 (m, 1H), 2.08-2.15 (m, 1H), 2.19-2.27 (m,
1H), 2.33-2.54 (m, 3H), 3.66-3.72 (m, 1H), 3.80 (dd, J =10.6, 5.5 Hz, 1H), 4.22 (dd, J
=8.8 Hz, 1H) 13C NMR (126MHz, CDCl3) δ= 208.2, 81.7, 80.9, 62.8, 48.9, 32.5, 32.1,
31.7, 26.7, 25.8, 18.2, -5.5, -5.6; HRMS (DART) calcd for C15H29O3 Si [M+H]+:
285.1886; found 285.1880.
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3-Allyl-6-(tert-Butyl-dimethyl-silanyloxymethyl)-5-methyl-8-oxa-bicyclo[3.2.1]octan-2one (187)
Ketone 186 (0.078g, 0.274mmol) was dissolved in THF (6mL) and treated with 1.0M
solution of LHMDS in THF (0.274ml) at -78°C and allowed to stir 30mins under an
argon atmosphere.

To the solution was added allyl iodide dropwise (0.25mL,

0.548mmol) and the reaction continued to stir vigorously while being monitored by TLC
(12% EtOAc in hexanes). Once the reaction was complete, it was quenched with sat. aq.
NH4Cl (4mL) and diluted with EtOAc (5mL). The biphasic mixture was placed in a
separatory funnel to remove organic layer.

Extraction of the aqueous layer was

performed with EtOAc (3x 5mL). The combined ethereal layers were washed with brine
(5mL), dried over Na2SO4, and concentrated in vacuo The solvent was removed under
vacuum and the residue was purified by flash chromatography (SiO2, 2g, 10% EtOAc in
hexanes) to give ketone 187 (0.058g, 67%) as a clear oil; Rf = 0.45 (12% EtOAc in
hexanes); IR (KBr, cm-1): υ: 838, 1295, 1717, 2931, 2960; 1H NMR (500MHz CDCl3):
δ= 0.08 (s,6H), 0.91 (s,9H), 1.42 (s, 3H), 1.56-1.60 (dd, J=5, 10Hz, 1H), 1.67-1.72 (m,
1H), 2.08-2.12 (m, 1H), 2.25-2.27 (m, 2H), 2.58-2.66 (ddd, J=10, 5, 10Hz, 3H), 3.733.86 (dd, J= 15, 15Hz, 2H), 4.23-4.24 (d, J= 5Hz, 1H), 5.05-5.08 (m, 2H), 5.69-5.74 (m,
1H)

13

C NMR (126MHz, CDCl3) δ= 207.8, 135.5, 117.3, 82.8, 80.8, 63.1, 49.2, 41.2,
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40.2, 34.5, 32.1, 26.5, 26.1, 18.5, -5.3, -5.4; HRMS (DART) calcd for C18H33O3 Si
[M+H]+: 325.2199; found 325.2197.

3-Allyl-6-hydroxymethyl-5-methyl-8-oxa-bicyclo[3.2.1]octan-2-one (187b)
Silyl ether 187 (0.197, 0.607mmol) was dissolved in dry THF (3.4mL, 0.18mM) in
plastic vessel tube at room temperature. The solution was cooled to 0°C following slow
addition of conc. HF/pyridine (0.16mL, 9.11mmol). After 5mins the ice bath was
removed allowing the mixture to reach room temperature. The reaction was complete
after stirring about 1h at this temperature. Quenching of the reaction was done by
dropwise addition of the acid to sat.aq. NaHCO3 solution.

The aqueous layer was

extracted with EtOAc (3 x 4mL) and the organics were collected. Washing the organics
with brine (4mL), drying over Na2SO4, filtered, and removal of solvent in vacuo led to
crude alcohol 187b as a clear oil. By TLC the product was slightly above baseline: [Rf=
0.13(3:1 Hexane:EtOAc solution)].
Toluene-4-sulfonic acid 3-allyl-5-methyl-2-oxo-8-oxa-bicyclo[3.2.1]oct-6ylmethylester
(189)
The crude alcohol 187b (0.607mmol) obtained was added to dry dichloromethane
(0.18mM) at room temperature. Sequentially to the solution was added Et3N (0.25mL,
1.82mmol), DMAP (0.222g, 1.82mmol) and p-toluenesulfonylchloride (0.344g,
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1.82mmol). Stirring at ambient temperatures and careful monitoring by TLC (25%
EtOAc in hexanes) showed complete consumption of the starting material after 15mins.
The mixture was diluted with CH2Cl2 (4mL) and poured into H2O (5mL). The aqueous
layer was extracted with (3x 5mL) and the combined organics were washed with H2O
(5mL) and brine (5mL), dried over Na2SO4, filtered, and concentrated in vacuo to give
crude tosylate 189 as an orange solid: [Rf=0.22 (25%EtOAc in hexanes)].
5-Allyl-3-methyl-2-oxa-tricyclo[3.3.1.0]3’,7’nonan-9-one (190)
To a solution of crude tosylate (0.607mmol) obtained above in dry benzene (12.14mL,
0.05mM) was slowly added a 1.0M solution of tBuOK in tBuOH (0.79mL) at room
temperature.

The alkaline solution was stirred for an additional 20 min before the

addition of sat. aq. NaHCO3( 10mL). The benzene and tBuOH were removed under
reduced pressure and the remaining aqueous layer was extracted with EtOAc (3x 10mL).
The combined organics were washed with brine (10mL), dried over Na2SO4, filtered, and
concentrated in vacuo. The crude residue was purified by flash chromatography (SiO2, 2
grams, 10% EtOAc in hexanes) to afford ketone 190 (0.067g, 58%, 3 steps) as oil: Rf=
0.70 (25% EtOAc in hexanes); IR (KBr, cm-1): υ: 908, 1110, 1372, 1713, 1721, 2253; 1H
NMR (500MHz CDCl3): δ= 1.52 (s,3H), 1.54-1.55 (d, J=5Hz, 1H), 1.78-1.83 (m, 2H),
1.92-1.96 (m, 1H), 2.12-2.15 (dd, J=5, 5 Hz, 1H), 2.20-2.26 (m, 1H), 2.34-2.38 (dd, J=5,
5Hz, 1H), 2.52-2.54 (t, 1H), 4.23-4.24 (d, J=5 Hz, 1H), 5.00-5.03 (m, 2H), 5.73-5.82 (m,
1H)

13

C NMR (126MHz, CDCl3) δ= 209.3, 134.3, 117.6, 87.2, 84.2, 58.2, 53.2, 47.1,

44.9, 42.9, 35.6, 22.7; HRMS (DART) calcd for C12H17O2 [M+H]+: 193.1229; found
193.1210.
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3-Methyl-5-(2-oxo-propyl)-2-oxa-tricyclo[3.3.1.0]3’,7’nonan-9-one(191)
Oxidation of the terminal vinyl group was done according to the Wacker reaction
procedure. PdCl2 (15 mmol%) and Cu(OAc)2 ( 0.126g, 0.634 mmol) were added to
flame dried flask purged with argon followed by addition of DMF:H2O (6.34 mL)
solution. The mixture was stirred for 1 hour under an O2 atm.via balloon. Next alkene
190 (0.122g, 0.634mmol) was dissolved in DMF to make a 0.5mM solution and added to
the flask dropwise. The balloon was removed and oxygen was continuously bubbled
throughout the flask while stirring at room temperature. The reaction was monitored by
TLC (25%EtOAc in hexanes) until deemed complete. Upon complete oxidation the
reaction was quenched with distilled H2O (3mL) and poured into a separatory funnel.
The aqueous layer was extracted with EtOAc (3x 10mL). The combined organics were
washed with brine (10mL), dried over Na2SO4, filtered, and concentrated in vacuo. The
crude residue was purified by flash chromatography (SiO2, 4 grams, 12% EtOAc in
hexanes) to afford diketone 191 (0.080g, 60%) as an oil. Rf= 0.30 (25% EtOAc in
hexanes); IR (KBr, cm-1): υ: 906, 1189, 1446, 1727, 2926, 2976; 1H NMR (500MHz
CDCl3): δ= 1.52 (s,3H), 1.85-1.87 (d, J =10Hz, 2H), 1.89-1.90 (d, J =5Hz, 1H), 1.98-2.03
(m, 1H), 2.20 (m, 1H), 2.22-2.25 (m, 1H), 2.45 (dd, J =3.5, 5 Hz, 1H), 2.50-2.53 4.22 (d,
J =15 Hz, 2H), 2.58 (s,1H), 4.25-4.26 (d, J =5 Hz, 1H) 13C NMR (126MHz, CDCl3) δ=
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208.3, 206.5, 86.8, 83.6, 60.5, 57.3, 53.9, 47.5, 44.4, 44.2, 42.6, 31.4, 22.4, 21.1, 14.3;
HRMS (DART) calcd for C12H17O3 [M+H]+: 209.1178; found 209.1160.

To the diketone 191 (0.093g, 0.447mmol) in benzene (17.8mL) was added a 1.0M
solution of t-BuOK/t-BuOH (0.893mL) base at ambient temperature. The mixture was
allowed to stir continuously until complete condensation of the starting material which
was monitored by TLC (25% EtOAc in hexanes). Addition of sat. aq. NaHCO3 to the
alkaline solution after 20mins was used to quench the reaction. The benzene and tBuOH
were removed under reduced pressure and the remaining aqueous layer was extracted
with EtOAc (3x 10mL). The combined organics were washed with brine (10mL), dried
over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by flash
chromatography (SiO2, 2 grams, 25% EtOAc in hexanes) to afford tetracyclic pentenone
192 (0.029g, 58%) as oil: Rf= 0.25 (25% EtOAc in hexanes); IR (KBr, cm-1): υ: 917,
1243, 1631, 1709, 2249, 2969; 1H NMR (500MHz CDCl3): δ= 1.49 (s, 3H), 1.53-1.56
(m, 1H), 1.83-1.85 (d, J= 10Hz, 1H), 1.95 (s, 1H), 1.96-1.97 (d, J=5 Hz 1H), 2.12-2.14
(m, 1H), 2.27-2.29 (m, 1H), 2.34-2.36 (d, J =10 Hz, 1H), 2.50-2.53 (d, J =15 Hz, 1H),
5.02-5.03 (d, J= 5,1H), 5.80 (s, 1H); 13C NMR (126MHz, CDCl3) δ= 180.2, 171.3, 122.7,
87.1, 76.3,

60.6, 53.7, 52.5, 47.9, 45.2, 42.8, 42.2, 29.9, 22.9, 21.3, 14.4; HRMS

(DART) calcd for C12H15O2 [M+H]+: 191.1072; found 191.1060.
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To enone 192 (0.029g, 0.152mmol), [Rh(cod)2]BF4 (0.0123g, 0.030mmol), (4R,5R)DIOP (0.0152g, 0.030) were placed in a dry glass vial and dissolved in 1,2dichloroethane (3.04mL). The vial was placed in a hydrogenation chamber and purged
three times (H2) prior to pressurizing the reaction vessel with H2 (600psi). The reaction
mixture was allowed to stand (no stirring) for 8h before carefully releasing the pressure.
Because TLC revealed a large amount of an over-reduced by product (Rf= 0.27, 50%
EtOAc in hexanes), the solution was placed under an atmosphere of argon and solid
NaHCO3 (0.128g, 1.52mmol) and Dess-Martin periodinane (0.129g, 0.304mmol) were
added [Note: This over-reduction was seen in our previous reported synthesis of
platensimycin]. The mixture was stirred at room temperature for 1h before addition of
sat. aq.NaHCO3 (3mL). The biphasic mixture was stirred for an additional 1h before
diluting the reaction with CH2Cl2 (5mL). The layers were separated and the aqueous
layer extracted with CH2Cl2 (3x5mL). The combined organics were washed with brine
(10mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was
purified by flash chromatography (SiO2, 1 gram, 25% EtOAc in hexanes) to afford
ketone 193 and its C9 diastereomer (0.014g, 48%, 2:1 mixture) as an oil: Rf= 0.25 (25%
EtOAc in hexanes); IR(KBr, cm-1):υ: 912, 1363, 1712, 1740, 2250, 2956; 1H NMR
(500MHz CDCl3): δ= 1.45 (s, 3H), 1.58 (s, 1H), 1.83-1.85 (d, J= 10Hz, 2H), 1.90-1.92
(d, J= ,1H), 1.95-1.99 (m, 1H), 2.08-2.09 (s, 1H), 2.22-2.30 (m, 3H), 2.35-2.39 (m, 1H),
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4.46 (s, 1H);

13

C NMR(126MHz,CDCl3) δ=197.1, 87.2, 78.2, 50.6, 49.1, 47.6, 45.4,

45.2,42.4,39.6,37.2, 23.5;HRMS (ESI) calcd for C12H16O2[M+H]+:193.1229;found
193.1210.
O
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6-Hydroxymethyl-5-methyl-8-oxa-bicyclo[3.2.1]octan-2-one (181)
The ketone 186 (0.348, 1.07mmol) was dissolved in dry THF (6mL, 0.18mM) in plastic
vessel tube at room temperature. The solution was cooled to 0°C following slow addition
of conc. HF/pyridine (0.28mL, 16.05mmol). After 5mins the ice bath was removed
allowing the mixture to reach room temperature. The reaction was complete after stirring
about 1h at this temperature. Quenching of the reaction was done by dropwise addition
of the acid to sat.aq.NaHCO3 solution. The aqueous layer was extracted with EtOAc (3 x
5mL) and the organics were collected. Washing the organics with brine (4mL), drying
over Na2SO4, filtered, and removal of solvent in vacuo led to a crude alcohol 181 as a
clear oil. By TLC the product was slightly above baseline: [Rf= 0.07(3:1 Hexane:EtOAc
solution)].
Toluene-4-sulfonic acid 3-allyl-5-methyl-2-oxo-8-oxa-bicyclo[3.2.1]oct-6ylmethylester
(188)
The crude alcohol (1.07mmol) obtained was added to dry dichloromethane (0.18mM) at
room temperature. Sequentially to the solution was added Et3N (0.22mL, 1.61mmol),
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DMAP (0.261g, 1.61mmol) and p-toluenesulfonylchloride (0.304g, 1.61mmol). Stirring
at ambient temperatures and careful monitoring by TLC (25% EtOAc in hexanes) showed
complete consumption of the starting material after 2h. The mixture was diluted with
CH2Cl2 (4mL) and poured into H2O (5mL). The aqueous layer was extracted with (3x
5mL) and the combined organics were washed with H2O (5mL) and brine (5mL), dried
over Na2SO4, filtered, and concentrated in vacuo to give crude tosylate as an orange
solid. The crude residue was purified by flash chromatography (SiO2, 6 grams, 25%
EtOAc in hexanes) to afford ketone 188 (0.237g, 68%, 2steps) as oil: Rf= 0.31 (25%
EtOAc in hexanes); IR (KBr, cm-1): υ: 1035, 1478, 1813, 1959, 3070, 3090; 1H NMR
(500MHz CDCl3): δ= 1.42 (s,3H), 1.44-1.48 (dd, J=5, 5Hz, 1H), 1.94-1.96 (d, J=10Hz,
1H), 2.02-2.06 (m, 1H), 2.32-2.44 (m, 3H), 2.48 (s, 3H), 2.51 (m, 1H), 4.11-4.18 (dd,
J=10, 5Hz, 2H), 4.23-4.25 (d, J=10Hz, 1H), 7.38-7.40 (d, J=10Hz, 2H), 7.80-7.82 (d,
J=10Hz, 2H),
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C NMR (126MHz, CDCl3) δ= 206.9, 145.5, 132.6, 130.2, 127.9, 81.4,

80.6, 77.5, 77.2, 77.0, 69.4, 45.9, 32.4, 32.1, 31.6, 26.4, 21.8; HRMS (DART) calcd for
C16H21O5Si [M+H]+: 325.1110; found 325.1094.
O

O

199

CH 3

3-Methyl-2-oxa-tricyclo[3.3.1.0]3’,7’nonan-9-one (199)
To a solution of pure tosylate 188 (0.129g, 0.398mmol) obtained above in dry benzene
(7.96mL, 0.05mM) was slowly added a 1.0M solution of tBuOK in tBuOH (0.52mL) at
room temperature. The alkaline solution was stirred for an additional 20 min before the
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addition of sat.aq.NaHCO3 (10mL). The benzene and tBuOH were removed under
reduced pressure and the remaining aqueous layer was extracted with EtOAc (3x 10mL).
The combined organics were washed with brine (10mL), dried over Na2SO4, filtered, and
concentrated in vacuo. The crude residue was purified by flash chromatography (SiO2, 2
grams, 10% EtOAc in hexanes) to afford ketone 199 (0.067g, 68%) as oil: Rf= 0.70
(25% EtOAc in hexanes); IR (KBr, cm-1): υ: 909, 1031, 1446, 1731, 2225, 2970; 1H
NMR (500MHz CDCl3): δ= 1.50 (s,3H), 1.72-175 (d, J=15Hz, 1H), 1.81-1.86 (m, 2H),
2.01 (m, 1H), 2.22 (m, 1H), 2.27-2.30 (d, J=15Hz 1H), 2.50 (s, 1H), 2.76, (s,1H), 4.14
(s,1H)

13

C NMR (126MHz, CDCl3) δ= 209.7, 86.5, 84.2, 52.3, 49.6, 44.2, 42.9, 22.7;

HRMS (DART) calcd for C9H13O2 [M+H]+: 153.0916; found 153.0892.

3(3-Methyl-2-oxa-tricyclo[3.3.1.0]3’,7’non-9ylamino)propionic acid t-butyl ester (200)
Tricyclic ketone 199 (0.102g, 0.670mmol) was dissolved in dry MeOH (3.53mL,
0.19mM) followed by addition of Ti(iOPr)4 (0.250mL, 0.838mmol). A solution of βAlanine-t-Butylester hydrochloride (0.152g, 0.838mmol) in MeOH (1mL) was slowly
added to the white cloudy mixture. After stirring 1-2h at room temperature, the MeOH
was removed under reduced pressure and the remaining white solid residue was
redissolved in CH2Cl2 (2.03mL, 0.33mM). The imine formation was monitored by TLC
and sat slightly above the baseline. [Rf=0.10 (5% MeOH in CH2Cl2)] The cloudy solution
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was cooled to 0°C followed by addition of soild NaBH(OAc)3 (0.178g, 0.838mmol) in
one portion to the round bottom flask. Warm up the mixture to 25°C after 5 mins of
stirring until the reduction was complete. Finally quench with H2O (6mL), dilute with
CH2Cl2, and filter thru Celite. Extract the aqueous layer with CH2Cl2 (3x 8mL). The
combined organics were washed with brine (8mL), dried over Na2SO4, filtered, and
concentrated in vacuo. The crude residue was purified by flash chromatography (SiO2,
3.0 grams, 5% MeOH in CH2Cl2 ) to afford amine 200 (0.120g, 64%) as yellow solid:
Rf= 0.6 (10% MeOH in CH2Cl2); IR (KBr, cm-1): υ: 650, 733, 908, 1155, 2253, 2974; 1H
NMR (500MHz CDCl3): δ= 1.35 (s,3H), 1.39 (s, 9H), 1.52-1.55(dd, J=10, 5Hz, 1H),
1.57-1.59 (d, J=10 Hz, 2H), 1.88-1.90 (s, J=10Hz, 2H), 2.17-2.19 (m, 2H), 2.32 (s, 1H),
2.58 (s, 1H), 2.81-2.84 (t, 2H), 3.00 (s, 1H), 3.05-3.06 (d, J=5 Hz, 2H), 4.40 (s, 1H) 13C
NMR (126MHz, CDCl3) δ= 170.5, 86.4, 81.4, 58.7, 46.1, 44.2, 42.4, 39.0, 38.4, 36.9,
28.5, 22.9, 22.5; HRMS (ESI) calcd for C16H27O3 N [M+H]+: 282.2069; found 282.2070

3-Acetyl-(3-Methyl-2-oxa-tricyclo[3.3.1.0]3’,7’non-9-yl)-amino-propionic acid t-butyl
ester (201)
Tricyclic amine 200 (0.067g, 0.238mmol) was dissolved in dry CH2Cl2 (1.19mL, 0.2mM)
followed by addition of pyridine (0.024mL, 0.298mmol), and DMAP (10%mmol). Once
everything was in solution Ac2O (0.030mL, 0.298mmol) was added at ambient
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temperature. The mixture was stirred vigorously for 1h or until complete consumption of
starting amine (monitored by TLC 5%MeOH in CH2Cl2). Quench with aqueous
sat.NH4Cl followed by dilution with CH2Cl2 (2.0mL). Extract the aqueous layer with
CH2Cl2 (3x 5mL). The combined organics were washed with brine (5mL), dried over
Na2SO4, filtered, and concentrated in vacuo. Amide 201 was obtained in 45% yield as
yellow oil. The residue without any further purification was treated with concentrated
15-20 equiv. of trifluoroacetic acid for hydrolysis to yield crude carboxylic acid 202: Rf=
0.85 (10% MeOH in CH2Cl2); IR (KBr, cm-1): υ: 735, 1149, 1308, 1646, 1725, 2333,
2929, 2974; 1H NMR (500MHz CDCl3): δ= 1.25 (s,3H), 1.44 (s, 9H), 1.59-1.62(d, J=15,
1H), 1.71 (s, 1H), 1.78 (m, 2H), 2.01-2.03 (d, J=10, 2H), 2.14 (s, 3H), 2.28 (s, 1H), 2.43
(s, 2H), 2.53 (m, 1H), 3.76 (s, 1H), 4.20 (s, 1H) 13C NMR (126MHz, CDCl3) δ= 172.0,
86.6, 81.2, 79.1, 43.7, 41.2, 39.9, 39.0, 29.8, 28.3, 22.9, 22.6.
OH

OH

MeO2C

MeO2C

OH
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Dihydroxy benzoate 203 (3.00g, 17.84mmol) was dissolved in a 2:1mixture of AcOHAc2O solution (36mL, 0.5mM) via ultrasonication. The mixture was cooled to 0°C and
HNO3 (1.24g, 19.63mmol) in AcOH (9.8mL) added dropwise over 1 min. Once complete
allow to warm up to ambient temperature and stir 15 min. Next H2O (46mL) was added
to the brownish colored mixture forming solid precipitate in the reaction flask. Filter off
solids and rinse with small amount of water, then dry under vacuum to obtain a crude
beige solid. This solid product is not the correct isomer. Collect the clear brown solution
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and combined washings, then extract with EtOAc; wash with brine, dry over sodium
sulfate,filter, and removal of solvents in vacuo provided a crude orange product. This
compound was found to be the desired regioisomer. Nitro ester 204 was obtained in %
yield as yellow solid needles upon purification on SiO2 (3:1 then 1:1 Hex:EtOAc
solution) by flash chromatography. Rf= 0.13 (25% EtOAc in n-hexanes); 1H NMR
(500MHz CDCl3): δ= 3.98 (s, 3H), 6.62-6.64 (d, J=5 Hz, 1H), 7.98-8.00 (d, J=5 Hz,
1H), 11.19 (s, 1H), 12.87 (s, 1H)

13

C NMR (126MHz, CDCl3) δ= 170.1, 160.9, 160.3,

136.9, 109.5, 53.1.[All data matches up with those reported by Giannis et.al.]
The nitrobenzoate 204 (0.769g, 3.63mmol) was dissolved in EtOAc (8mL) in a purged
flask. Next Pd/C (10%mmol) was added and continuously stirred at room temperature
under hydrogen atmosphere (provided by H2 balloon) for 16h. The reaction was
monitored by TLC. Once hydrogenation was complete, the mixute was filterd through a
plug of silica and washed with EtOAc. The organic solvent was removed in vacuo to
provide the primary amine 205.
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Silyl enol ether 163
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Compound 163 vs. Ferrocine
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